var title_f22_51_23344="Squamocolumnar junction";
var content_f22_51_23344=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F64778&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F64778&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cervical squamocolumnar junction",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 328px; height: 311px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The current junction where the squamous and columnar cells meet on the surface of the cervix at the time the patient is being evaluated; it demarcates the junction of the endocervical glandular epithelium and the squamous epithelium after squamous metaplasia is completed.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: O'Connor, DM, Brotzman, GL, Apgar, BS. Glossary. In: Colposcopy Principles and Practice, Apgar, BS, Brotzman, GL, Spitzer, M (Eds), W.B. Saunders Company, Philadelphia 2002. p.137. Copyright &copy; 2002 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_51_23344=[""].join("\n");
var outline_f22_51_23344=null;
var title_f22_51_23345="Necrotizing ulcerative gingivitis";
var content_f22_51_23345=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F62639&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F62639&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Two-year-old malnourished child",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The child presented with facial swelling, angular cheilosis, and skin lesions, particularly around the nose. Intra oral examination showed necrotizing ulcerative gingivitis involving the posterior right quadrant of the maxilla.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Originally published in: Enwonwu CO, Phillips RS, Falkler WA Jr. Nutrition and oral infectious diseases: state of the science. Compendium 2002; 23:431. Copyright &copy; 2002 AEGIS Publications, LLC. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_51_23345=[""].join("\n");
var outline_f22_51_23345=null;
var title_f22_51_23346="Patient information: Sterilization for women (The Basics)";
var content_f22_51_23346=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/86792\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/52/15171\">",
"         Female reproductive anatomy",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?13/56/14211\">",
"         Patient information: Choosing birth control (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?12/28/12738\">",
"         Patient information: Emergency contraception (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?1/22/1378\">",
"         Patient information: Long-acting methods of birth control (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?8/60/9157\">",
"         Patient information: Birth control; which method is right for me? (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?4/16/4355\">",
"         Patient information: Long-term methods of birth control (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Sterilization for women (The Basics)",
"    </div>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H89192597\">",
"      <span class=\"h1\">",
"       What is sterilization for women?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Sterilization is a procedure that prevents pregnancy any time in the future. For a woman, the procedure is called &ldquo;tubal ligation&rdquo; or &ldquo;having your tubes tied.&rdquo; For this procedure, a doctor seals the tubes that carry eggs from the ovaries to the uterus. These tubes are called the fallopian tubes (",
"      <a class=\"graphic graphic_figure graphicRef80271 \" href=\"UTD.htm?14/52/15171\">",
"       figure 1",
"      </a>",
"      ).",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H89192743\">",
"      <span class=\"h1\">",
"       How is sterilization for women done?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Sterilization for women involves surgery. It is usually done in a hospital but sometimes in a doctor&rsquo;s office.",
"     </p>",
"     <p>",
"      The 3 types of surgery include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Laparoscopic sterilization &ndash; For this procedure, you will get medicines through a small tube put into a vein, called an &ldquo;IV.&rdquo; You also might breathe gases through a mask to make you unconscious. This is called &ldquo;general anesthesia.&rdquo; The doctor will then insert a tiny camera and tools through small incisions (cuts) in your lower belly. Next the doctor will use rings or clips to close your fallopian tubes. Or the doctor might use heat to seal the tubes shut. Most women are back to normal after 1 to 2 weeks.",
"       </li>",
"       <li>",
"        Postpartum (done after giving birth) sterilization &ndash; If you have a vaginal delivery, this procedure will be done 1 to 2 days after you have a baby, while you are still recovering in the hospital. First, you will get a &ldquo;spinal block.&rdquo; For a spinal block, the doctor will put a small needle in your lower back, into the fluid around your spinal cord. Then the doctor will inject medicines that block pain and relax your muscles so you do not move. Next the doctor will make a small cut below your belly button and take out a small section of each fallopian tube.",
"        <br/>",
"        <br/>",
"        If you have your baby through an incision in your belly (called a &ldquo;C-section&rdquo;), the doctor can do the sterilization procedure right afterward, through the same incision.",
"        <br/>",
"        <br/>",
"        Getting sterilized after giving birth doesn&rsquo;t keep you in the hospital for extra time. This is true if you have either a vaginal delivery or a C-section.",
"       </li>",
"       <li>",
"        Hysteroscopic sterilization &ndash; For this procedure, the doctor will inject a pain-blocking medicine near your cervix. He or she will also give you pain-relieving pills. You might also get medicine to help you relax and feel sleepy. Then the doctor will insert a tool through your cervix and uterus and use it to place a tiny metal coil inside each of your fallopian tubes. The coil is called Essure. This procedure involves no cuts and is less painful and has a shorter recovery time compared to the other 2 procedures.",
"        <br/>",
"        <br/>",
"        You must use a different form of birth control for 3 months after this procedure. At that time, you will return to the doctor for an X-ray to make sure both of your fallopian tubes are blocked.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H89192629\">",
"      <span class=\"h1\">",
"       How well does sterilization for women work?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Sterilization for women is very effective. Less than 1 percent of women who have these procedures get pregnant.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H89192646\">",
"      <span class=\"h1\">",
"       What are the benefits and downsides sterilization for women?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The main benefit of sterilization is that it is permanent and doesn&rsquo;t require further medicines or procedures to prevent pregnancy. The downside is that women sometimes change their mind and regret getting sterilized.",
"     </p>",
"     <p>",
"      Women who DO get pregnant after sterilization have a high risk of an &ldquo;ectopic&rdquo; pregnancy. When this happens, a woman&rsquo;s egg joins with a man&rsquo;s sperm to form an embryo. But instead of attaching to the lining of the uterus, the embryo attaches to a place in the body where it should not attach and starts to grow. This can be dangerous. If you have had a sterilization procedure and think you are pregnant, call your doctor right away.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H89192663\">",
"      <span class=\"h1\">",
"       What if I change my mind and want to get pregnant?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Women who are sterilized can have another procedure to try to reverse the sterilization. But this often does not work and can be very expensive. The most common reason woman changes her mind is marriage (either a first marriage or a later marriage after an earlier marriage ends).",
"     </p>",
"     <p>",
"      Women sometimes also change their mind if they:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Had marriage or relationship problems when they got sterilized",
"       </li>",
"       <li>",
"        Had complications during a recent pregnancy",
"       </li>",
"       <li>",
"        Were younger than 30 when they got sterilized",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If you are in any of those situations, your doctor might suggest that you try a different form of birth control until you are certain about your decision.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H89192680\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?13/56/14211?source=see_link\">",
"       Patient information: Choosing birth control (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?1/22/1378?source=see_link\">",
"       Patient information: Long-acting methods of birth control (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?12/28/12738?source=see_link\">",
"       Patient information: Emergency contraception (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?4/16/4355?source=see_link\">",
"       Patient information: Long-term methods of birth control (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?8/60/9157?source=see_link\">",
"       Patient information: Birth control; which method is right for me? (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?22/51/23346?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 86792 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-89.32.226.102-36135ECCB4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_51_23346=[""].join("\n");
var outline_f22_51_23346=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H89192597\">",
"      What is sterilization for women?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H89192743\">",
"      How is sterilization for women done?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H89192629\">",
"      How well does sterilization for women work?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H89192646\">",
"      What are the benefits and downsides sterilization for women?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H89192663\">",
"      What if I change my mind and want to get pregnant?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H89192680\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/86792\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/52/15171\">",
"      Female reproductive anatomy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?8/60/9157?source=related_link\">",
"      Patient information: Birth control; which method is right for me? (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?13/56/14211?source=related_link\">",
"      Patient information: Choosing birth control (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?12/28/12738?source=related_link\">",
"      Patient information: Emergency contraception (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?1/22/1378?source=related_link\">",
"      Patient information: Long-acting methods of birth control (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?4/16/4355?source=related_link\">",
"      Patient information: Long-term methods of birth control (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_51_23347="Alopecia areata eyelash";
var content_f22_51_23347=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F72738&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F72738&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Alopecia areata involving the eyelashes",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Lateral eyelashes are absent in this patient with alopecia areata.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_51_23347=[""].join("\n");
var outline_f22_51_23347=null;
var title_f22_51_23348="Antihemophilic factor/von Willebrand factor complex (human): Patient drug information";
var content_f22_51_23348=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Antihemophilic factor/von Willebrand factor complex (human): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/0/39942?source=see_link\">",
"     see \"Antihemophilic factor/von Willebrand factor complex (human): Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/22/9575?source=see_link\">",
"     see \"Antihemophilic factor/von Willebrand factor complex (human): Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F3000299\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Alphanate&reg; ;",
"     </li>",
"     <li>",
"      Humate-P&reg;;",
"     </li>",
"     <li>",
"      Wilate&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F4663155\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Humate-P&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10016506\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691879",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat hemophilia.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat von Willebrand disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691426",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop and treat bleeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10016505\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701531",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to antihemophilic factor/von Willebrand factor complex (human) or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10016509\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10016510\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698333",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Short-term pain after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697859",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Allergic side effects may rarely happen.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Gallbladder disease, blood clots, heart attacks, and other blood vessel problems may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10016512\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698626",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698619",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in strength on 1 side is greater than the other, trouble speaking or thinking, change in balance, or blurred eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699117",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Weakness, numbness, or tingling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10016508\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695991",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695961",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may be given at home.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696360",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Your doctor may teach you how to give the shot.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696118",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Throw away needles in a needle/sharp disposal box and take the box back to your doctor when it is full.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10016513\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699650",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Most of the time, this drug will be given to you in a doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699197",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If this drug is given at home, store unopened vials in a refrigerator. Do not freeze.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699190",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Humate-P&reg;: You may also store unopened vials at room temperature. Throw away any unused vials after the date on the bottle has passed.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699148",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Alphanate&reg;: Or store unopened vials at room temperature. Throw away any unused vials after 2 months.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2995619",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wilate&reg;: Or store unopened vials at room temperature. Throw away any unused vials after 6 months.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10016514\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11523 Version 29.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-60.18.131.125-6AD27EA953-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_51_23348=[""].join("\n");
var outline_f22_51_23348=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3000299\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4663155\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016506\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016505\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016509\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016510\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016512\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016508\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016513\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016514\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?39/0/39942?source=related_link\">",
"      Antihemophilic factor/von Willebrand factor complex (human): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/22/9575?source=related_link\">",
"      Antihemophilic factor/von Willebrand factor complex (human): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_51_23349="Hyaluronidase: Pediatric drug information";
var content_f22_51_23349=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Hyaluronidase: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?41/33/42512?source=see_link\">",
"    see \"Hyaluronidase: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?4/37/4691?source=see_link\">",
"    see \"Hyaluronidase: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F179308\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Amphadase&trade;;",
"     </li>",
"     <li>",
"      Hylenex;",
"     </li>",
"     <li>",
"      Vitrase&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1047693\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antidote, Extravasation",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11442601\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dehydration: Hypodermoclysis:",
"     </b>",
"     SubQ: 15 units added to each 100 mL of replacement fluid to be administered; dosing extrapolated from experience with larger volumes (ie, in older patients, 150 units facilitates absorption of &ge;1000 mL of solution). The volume of subcutaneous fluid administered is dependent upon the age, weight, and clinical condition of the patient, as well as laboratory determinations; maximum daily volume of clysis is 25 mL/kg/",
"     <b>",
"      day",
"     </b>",
"     and the rate of administration should not exceed 2 mL/minute",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Extravasation:",
"     </b>",
"     Limited data available: SubQ, intradermal: Use 5 separate 0.2 mL injections of a 15-150 units/mL solution into the extravasation site at the leading edge.",
"     <b>",
"      Note:",
"     </b>",
"     Some centers determine the concentration of  hyaluronidase based upon the volume of extravasation, so for smaller extravasation volumes  (&lt;100 mL), a less concentrated solution (15 units/mL) has been used;  to prepare 15 units/mL solution, dilute 0.1 mL of the 150 unit/mL solution in 0.9 mL NS",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1047687\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?41/33/42512?source=see_link\">",
"      see \"Hyaluronidase: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infants, Children, and Adolescents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Skin test:",
"     </b>",
"     Intradermal: 0.02 mL (3 units) of a 150 units/mL solution. Positive reaction consists of a wheal with pseudopods appearing within 5 minutes and persisting for 20-30 minutes with localized itching.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Dehydration:  Hypodermoclysis:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     SubQ prior to infusion: SubQ: 150 units, followed by subcutaneous isotonic fluid administration at a rate appropriate for age, weight, and clinical condition of the patient; 150 units facilitates absorption of &ge;1000 mL of solution. If the infusion is continued greater than 24 hours, additional doses have been administered at 24 hour intervals up to a total of 3 doses (Allen, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Added to replacement solution: Dose dependent on volume to be infused; 150 units of hyaluronidase facilitates the absorption of &ge;1000 mL of fluid; for patients (ie, neonates, young infants) who require smaller volumes for replacement fluid (&le;100 mL), 15 units added for every 100 mL of replacement fluid has been used at some centers; maximum daily dose: 150 units/",
"     <b>",
"      day",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Maximum clysis volumes:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Infants and Children &lt;3 years: Volume of a single clysis should not exceed 200 mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Children &ge;3 years and Adolescents: Rate and volume of a single clysis should not exceed those used for infusion of I.V. fluids",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Extravasation:",
"     </b>",
"     Limited data available: SubQ, intradermal: Use 5 separate 0.2 mL injections of a 150 units/mL solution into the extravasation site at the leading edge as soon as possible (preferably within 1 hour) after extravasation is recognized.",
"     <b>",
"      Note:",
"     </b>",
"     Some centers may determine concentration of hyaluronidase based upon volume of extravasation so for smaller volumes (&lt;100 mL), a less concentrated solution (15 units/mL) has been used;  to prepare 15 units/mL solution, dilute 0.1 mL of the 150 unit/mL solution in 0.9 mL NS",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Urography, subcutaneous:",
"     </b>",
"     SubQ: 75 units over each scapula followed by injection of contrast medium at the same site; patient should be in the prone position during drug administration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"     <b>",
"      Dehydration: Hypodermoclysis:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     SubQ prior to infusion: 150 units injected under skin, followed by subcutaneous isotonic fluid administration at a rate appropriate for age, weight, and clinical condition of the patient; 150 units facilitates absorption of &ge;1000 mL of solution",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Added to infusion solution: 15 units are added to each 100 mL of replacement fluid to be administered; administration at a rate appropriate for age, weight, and clinical condition of the patient; maximum dose: 150 units facilitates absorption of &ge;1000 mL of solution",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment in renal impairment:",
"     </b>",
"     All patients: There are no dosage adjustments provided in the manufacturer's labeling; hyaluronidase exerts its effects locally and is rapidly inactivated in the blood; adverse effects would not be expected.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment in hepatic impairment:",
"     </b>",
"     All patients: There are no dosage adjustments provided in the manufacturer's labeling; hyaluronidase exerts its effects locally and is rapidly inactivated in the blood; adverse effects would not be expected.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F179291\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hylenex: 150 units/mL (1 mL) [contains albumin (human), edetate disodium; derived from or manufactured using Chinese hamster ovary cells; recombinant]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hylenex: 150 units/mL (1 mL [DSC]) [contains albumin (human), edetate disodium; recombinant]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [bovine derived]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Amphadase&trade;: 150 units/mL (1 mL) [contains edetate disodium, thimerosal]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [ovine derived, preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Vitrase&reg;: 200 units/mL (1.2 mL) [contains lactose 0.93 mg/mL]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F179278\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1047697\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Parenteral: Treatment of extravasation: May administer undiluted (150 units/mL) or dilutions may be used for smaller volumes of extravasation. Infiltrate area of extravasation with 5 small injections at the leading edge; use 27- or 30-gauge needles and change needle between each skin entry to prevent bacterial contamination and minimize pain; do not administer I.V.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F179346\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in dextran 6% in dextrose, dextran 6% in NS, D",
"     <sub>",
"      5",
"     </sub>",
"     LR, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      4",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      10",
"     </sub>",
"     W, LR,",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Incompatible:",
"     </b>",
"     Hydromorphone.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Epinephrine, heparin, iothalamate meglumine 60%, iothalamate sodium 80%, pentobarbital, thiopental.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Hydromorphone.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Iodipamide meglumine 52%.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1047690\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphadase&trade;, Hylenex&trade;: Store intact vial at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F); do not freeze.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitrase&reg;: Store intact vial at 2&deg;C to 8&deg;C (35&deg;F to 46&deg;F); do not freeze. Protect from light. If adding to other injectable solutions, store admixture at 15&deg;C to 25&deg;C (59&deg;F to 77&deg;F) and use within 6 hours.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1047696\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adjunct therapy to increase the dispersion and absorption of other drugs; adjunct therapy to increase rate of absorption of parenteral fluids given by hypodermoclysis; adjunct therapy in subcutaneous urography for improving resorption of radiopaque agents (all indications: FDA approved in all ages); has also been used in the management of I.V. extravasations",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F179345\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Edema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Injection site reactions",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Allergic reactions, anaphylactic-like reactions (retrobulbar block or I.V. injections), angioedema, urticaria",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1047700\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to hyaluronidase or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1047686\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity reactions may occur; a preliminary intradermal skin test may be considered. Avoid use if positive reaction (ie, a wheal with pseudopods appears within 5 minutes and persists for 20-30 minutes accompanied by localized itching). Discontinue hyaluronidase if sensitization occurs during therapy. Use with caution in patients with reported history of bee sting allergy; hyaluronidase is an active component in bee venom (Lee, 2010).",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1047685\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not administer intravenously (enzyme is rapidly inactivated); do not inject in or around infected or inflamed areas; may spread localized infection. Do not apply directly to the cornea. Should",
"     <b>",
"      not",
"     </b>",
"     be used for dopamine and alpha-agonist drug infiltrates or to reduce swelling of bites or stings.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299453\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F179286\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha-/Beta-Agonists: Hyaluronidase may enhance the vasoconstricting effect of Alpha-/Beta-Agonists.  Management: Avoid the use of hyaluronidase to enhance dispersion or absorption of alpha-/beta-agonists.  Use of hyaluronidase for other purposes in patients receiving alpha-/beta-agonists may be considered as clinically indicated.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dipivefrin; EPINEPHrine (Nasal); Isometheptene; Pseudoephedrine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihistamines: May diminish the therapeutic effect of Hyaluronidase. Management: Patients receiving antihistamines (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids: May diminish the therapeutic effect of Hyaluronidase. Management: Patients receiving corticosteroids (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Beclomethasone (Nasal); Budesonide (Nasal); Ciclesonide (Nasal); Desonide; Dexamethasone (Ophthalmic); Difluprednate; Flunisolide (Nasal); Fluocinolone (Ophthalmic); Fluticasone (Nasal); Loteprednol; Mometasone (Nasal); PrednisoLONE (Ophthalmic); Triamcinolone (Nasal); Triamcinolone (Ophthalmic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     DOPamine: Hyaluronidase may enhance the adverse/toxic effect of DOPamine.  Management: Avoid the use of hyaluronidase to enhance dispersion or absorption of dopamine.  Use of hyaluronidase for other purposes in patients receiving dopamine may be considered as clinically indicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Estrogen Derivatives: May diminish the therapeutic effect of Hyaluronidase. Management: Patients receiving estrogens (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Local Anesthetics: Hyaluronidase may enhance the adverse/toxic effect of Local Anesthetics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Benzocaine; Benzydamine; Cocaine; Dibucaine; Dyclonine; Ethyl Chloride; Hexylresorcinol; Lidocaine (Ophthalmic); Lidocaine (Topical); Pramoxine; Proparacaine; Tetracaine (Ophthalmic); Tetracaine (Topical).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenylephrine (Systemic): Hyaluronidase may enhance the vasoconstricting effect of Phenylephrine (Systemic).  Management: Avoid the use of hyaluronidase to enhance dispersion or absorption of phenylephrine.  Use of hyaluronidase for other purposes in patients receiving phenylephrine may be considered as clinically indicated.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May diminish the therapeutic effect of Hyaluronidase. Management: Patients receiving salicylates (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F179288\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F179299\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no adequate or well-controlled studies in pregnant women; use only if clearly needed. Administration during labor did not cause any increase in blood loss or differences in cervical trauma. It is not known whether it affects the fetus if used during labor.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1047692\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Observe appearance of lesion for induration, swelling, discoloration, blanching, and blister formation every 15 minutes for &sim;2 hours",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1047684\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Modifies the permeability of connective tissue through hydrolysis of hyaluronic acid, one of the chief ingredients of tissue cement which offers resistance to diffusion of liquids through tissues; hyaluronidase increases both the distribution and absorption of locally injected substances",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1047699\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action by the SubQ or intradermal routes for the treatment of extravasation: Immediate",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: 24-48 hours",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F3421626\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?4/37/4691?source=see_link\">",
"      see \"Hyaluronidase: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Notify physician if pain, redness, swelling, unusual skin rash at or around injection site, swelling of mouth or lips; difficulty breathing or sudden dizziness occurs.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Allen CH, Etzwiler LS, Miller MK, et al, \"Recombinant Human Hyaluronidase-Enabled Subcutaneous Pediatric Rehydration,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2009, 124(5):e858-67.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/51/23349/abstract-text/19805455/pubmed\" id=\"19805455\" target=\"_blank\">",
"        19805455",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Flemmer L and Chan JS, \"A Pediatric Protocol for Management of Extravasation Injuries,\"",
"      <i>",
"       Pediatr Nurs",
"      </i>",
"      , 1993, 19(4):355-8, 424.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/51/23349/abstract-text/8414723/pubmed\" id=\"8414723\" target=\"_blank\">",
"        8414723",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lee A, Grummer SE, Kriegel D, et al, \"Hyaluronidase,\"",
"      <i>",
"       Dermatol Surg",
"      </i>",
"      , 2010, 36(7):1071-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/51/23349/abstract-text/20482727/pubmed\" id=\"20482727\" target=\"_blank\">",
"        20482727",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      MacCara ME, &ldquo;Extravasation: A Hazard of Intravenous Therapy,&rdquo;",
"      <i>",
"       Drug Intell Clin Pharm",
"      </i>",
"      , 1983, 17(10):713-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/51/23349/abstract-text/6628223/pubmed\" id=\"6628223\" target=\"_blank\">",
"        6628223",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Raszka WV, Keuser TK, Smith FR, et al, &ldquo;The Use of Hyaluronidase in the Treatment of Intravenous Extravasation Injuries,&rdquo;",
"      <i>",
"       J Perinatol",
"      </i>",
"      , 1990, 10(2):146-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/51/23349/abstract-text/2358898 /pubmed\" id=\"2358898 \" target=\"_blank\">",
"        2358898",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Spandorfer PR, Mace SE, Okada PJ, et al, \"A Randomized Clinical Trial of Recombinant Human Hyaluronidase-Facilitated Subcutaneous Versus Intravenous Rehydration in Mild to Moderately Dehydrated Children in the Emergency Department,\"",
"      <i>",
"       Clin Ther",
"      </i>",
"      , 2012, 34(11):2232-45.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/51/23349/abstract-text/23062548/pubmed\" id=\"23062548\" target=\"_blank\">",
"        23062548",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Zenk KE, Dungy CI, and Greene GR, &ldquo;Nafcillin Extravasation Injury: Use of Hyaluronidase as an Antidote,&rdquo;",
"      <i>",
"       Am J Dis Child",
"      </i>",
"      , 1981, 135(12):1113-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/51/23349/abstract-text/7315807/pubmed\" id=\"7315807\" target=\"_blank\">",
"        7315807",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13355 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-528937E1C1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_51_23349=[""].join("\n");
var outline_f22_51_23349=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179308\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047693\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11442601\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047687\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179291\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179278\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047697\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179346\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047690\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047696\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179345\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047700\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047686\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047685\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299453\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179286\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179288\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179299\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047692\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047684\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047699\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3421626\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13355\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13355|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?41/33/42512?source=related_link\">",
"      Hyaluronidase: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?4/37/4691?source=related_link\">",
"      Hyaluronidase: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_51_23350="Pyrimethamine: Drug information";
var content_f22_51_23350=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Pyrimethamine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?9/12/9413?source=see_link\">",
"    see \"Pyrimethamine: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/50/7973?source=see_link\">",
"    see \"Pyrimethamine: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F216093\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Daraprim&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F216094\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Daraprim&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F216127\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antimalarial Agent",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F216098\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Isosporiasis (",
"     </b>",
"     <b>",
"      <i>",
"       Isospora belli",
"      </i>",
"     </b>",
"     <b>",
"      infection) in HIV-positive patients",
"     </b>",
"     (unlabeled use; CDC, 2009): Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Treatment (alternative to trimethoprim-sulfamethoxazole):",
"     </i>",
"     50-75 mg once daily in combination with leucovorin calcium",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Chronic maintenance (secondary prophylaxis):",
"     </i>",
"     25 mg once daily in combination with leucovorin calcium",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Malaria chemoprophylaxis:",
"     </b>",
"     Oral:",
"     <b>",
"      Note:",
"     </b>",
"     Current CDC recommendations for malaria prophylaxis do not include the use of pyrimethamine; resistance to pyrimethamine is prevalent worldwide.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Manufacturer&rsquo;s labeling:",
"     </i>",
"     25 mg once weekly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Malaria treatment (non-",
"     </b>",
"     <b>",
"      <i>",
"       falciparum",
"      </i>",
"     </b>",
"     <b>",
"      malaria; use in conjunction with a sulfonamide [eg, sulfadoxine]):",
"     </b>",
"     Oral:",
"     <b>",
"      Note:",
"     </b>",
"     Current CDC recommendations for malaria treatment do not include the use of pyrimethamine; resistance to pyrimethamine is prevalent worldwide.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Manufacturer&rsquo;s labeling:",
"     </i>",
"     25 mg daily for 2 days; following clinical cure, administer a once-weekly chemoprophylaxis regimen for &ge;10 weeks.",
"     <b>",
"      Note:",
"     </b>",
"     Pyrimethamine use alone is",
"     <b>",
"      not",
"     </b>",
"     recommended; if circumstances arise where it must be used alone in semi-immune patients, give adults 50 mg daily for 2 days; then (following clinical cure) administer a once-weekly chemoprophylaxis regimen for &ge;10 weeks.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Pneumocystis jirovecii",
"      </i>",
"     </b>",
"     <b>",
"      pneumonia (PCP) in HIV-positive patients (unlabeled use; CDC, 2009):",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Prophylaxis (alternative to trimethoprim-sulfamethoxazole):",
"     </i>",
"     50 mg once weekly in combination with dapsone and leucovorin calcium;",
"     <b>",
"      or",
"     </b>",
"     25 mg once daily with atovaquone in combination with oral leucovorin calcium",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Chronic maintenance (secondary prophylaxis; alternative to trimethoprim-sulfamethoxazole):",
"     </i>",
"     50-75 mg once weekly in combination with dapsone and leucovorin calcium;",
"     <b>",
"      or",
"     </b>",
"     25 mg once daily with atovaquone in combination with leucovorin calcium",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Toxoplasmosis treatment:",
"     </b>",
"     Oral:",
"     <i>",
"      Manufacturer&rsquo;s labeling:",
"     </i>",
"     50-75 mg/day for 1-3 weeks depending on patient's tolerance and response, then may reduce dose by 50% and continue for 4-5 weeks; use with a sulfonamide in combination with leucovorin calcium",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Toxoplasmosis prophylaxis and treatment in HIV-positive patients (unlabeled; CDC, 2009):",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Prophylaxis for first episode of Toxoplasma gondii",
"     </i>",
"     (alternative to trimethoprim sulfamethoxazole): 50 mg or 75 mg once weekly with dapsone in combination with oral leucovorin calcium;",
"     <b>",
"      or",
"     </b>",
"     25 mg once daily with atovaquone in combination with oral leucovorin calcium",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Prophylaxis to prevent recurrence of  Toxoplasma gondii:",
"     </i>",
"     25-50 mg once daily with sulfadiazine in combination with leucovorin calcium (preferred);",
"     <b>",
"      or",
"     </b>",
"     25-50 mg once daily with clindamycin in combination with leucovorin calcium;",
"     <b>",
"      or",
"     </b>",
"     25mg once daily with atovaquone in combination with leucovorin calcium",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Treatment of Toxoplasma gondii encephalitis:",
"     </i>",
"     200 mg as a single dose, followed by 50 mg (&lt;60 kg) or 75 mg (&ge;60 kg) daily with sulfadiazine in combination with leucovorin calcium for at least 6 weeks (preferred);",
"     <b>",
"      or",
"     </b>",
"     200 mg as a single dose, followed by 50 mg (&lt;60 kg) or 75 mg (&ge;60 kg) daily with clindamycin, atovaquone, or azithromycin in combination with leucovorin calcium",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F216114\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/50/7973?source=see_link\">",
"      see \"Pyrimethamine: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Malaria chemoprophylaxis:",
"     </b>",
"     Oral: Begin prophylaxis before entering endemic area:",
"     <b>",
"      Note:",
"     </b>",
"     Current CDC recommendations for malaria prophylaxis do not include the use of pyrimethamine; resistance to pyrimethamine is prevalent worldwide.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Manufacturer&rsquo;s labeling:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children &lt;4 years: 6.25 mg once weekly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children 4-10 years: 12.5 mg once weekly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children &gt;10 years: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Malaria treatment (non-",
"     </b>",
"     <b>",
"      <i>",
"       falciparum",
"      </i>",
"     </b>",
"     <b>",
"      malaria; use in conjunction with a sulfonamide [eg, sulfadoxine]):",
"     </b>",
"     Oral:",
"     <b>",
"      Note:",
"     </b>",
"     Current CDC recommendations for malaria treatment do not include the use of pyrimethamine; resistance to pyrimethamine is prevalent worldwide.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Manufacturer&rsquo;s labeling:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children 4-10 years: 25 mg daily for 2 days; following clinical cure, administer a once-weekly chemoprophylaxis regimen for &ge;10 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children &gt;10 years: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Pyrimethamine use alone is",
"     <b>",
"      not",
"     </b>",
"     recommended; if circumstances arise where it must be used alone in semi-immune patients, give children 25 mg daily for 2 days, then (following clinical cure) administer a once-weekly chemoprophylaxis regimen for &ge;10 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Toxoplasmosis treatment:",
"     </b>",
"     Oral:",
"     <i>",
"      Manufacturer&rsquo;s labeling:",
"     </i>",
"     Loading dose: 1 mg/kg/day divided into 2 equal daily doses for 2-4 days, then may decrease dose to 0.5 mg/kg/day divided into 2 doses for 4 weeks; use with a sulfonamide and leucovorin calcium",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Toxoplasmosis prophylaxis and treatment in HIV-positive patients (unlabeled; CDC, 2009):",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Prophylaxis for first episode of Toxoplasma gondii:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children &ge;1 month of age: 1 mg/kg/day (or 15 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ) once daily (maximum: 25 mg), with dapsone or atovaquone, in combination with oral leucovorin calcium",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adolescents: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Prophylaxis to prevent recurrence of Toxoplasma gondii:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children &ge;1 month of age: 1 mg/kg/day (or 15 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ) once daily (maximum: 25 mg) given with sulfadiazine (or atovaquone or clindamycin), in combination with oral leucovorin calcium",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adolescents: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Treatment of congenital toxoplasmosis:",
"     </i>",
"     Infants and Children: Loading dose: 2 mg/kg/day once daily for 2 days, then 1 mg/kg/day once daily for 2-6 months, followed by 1 mg/kg administered 3 times weekly, in combination with leucovorin calcium and sulfadiazine (treatment duration: 12 months)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Treatment of acquired toxoplasmosis:",
"     </i>",
"     Infants and Children: Acute induction: Loading dose: 2 mg/kg once daily (maximum: 50 mg/day) for 3 days, then 1 mg/kg/day once daily (maximum: 25 mg/day), with sulfadiazine or clindamycin in combination with leucovorin calcium (treatment duration: &ge;6 weeks)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Treatment of Toxoplasma gondii encephalitis:",
"     </i>",
"     Adolescents:  Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F216099\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F216067\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Daraprim&reg;: 25 mg [scored]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F216052\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F216070\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer with meals to minimize GI distress.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F216068\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prophylaxis of malaria due to susceptible strains of plasmodia; used in conjunction with a sulfonamide for the treatment of uncomplicated malaria due to susceptible strains of plasmodia (alternative agent; not preferred therapy); synergistic combination with sulfonamide in treatment of toxoplasmosis",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F216134\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Daraprim&reg; may be confused with Dantrium&reg;, Daranide&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F216125\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Arrhythmias (large doses)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Erythema multiforme, rash, Stevens-Johnson syndrome, toxic epidermal necrolysis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Anorexia, atrophic glossitis, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Leukopenia, megaloblastic anemia,  pancytopenia, pulmonary eosinophilia,  thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Hematuria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylaxis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F216074\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to pyrimethamine or any component of the formulation; megaloblastic anemia secondary to folate deficiency",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F216056\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Folate deficiency: Use caution in patients with possible folate deficiency (eg, malabsorption syndrome, pregnancy, alcoholism).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; G6PD deficiency: Use with caution in patients with possible G6PD deficiency.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizure disorders: Use with caution in patients with a history of seizure disorders.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Leucovorin: When used for more than 3-4 days, it may be advisable to administer leucovorin calcium to prevent hematologic complications.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Monitoring: Monitor CBC and platelet counts every 2 weeks.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F216123\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2C9 (moderate)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F216061\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotic Agents (Phenothiazines): Antimalarial Agents may increase the serum concentration of Antipsychotic Agents (Phenothiazines).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Artemether: May enhance the adverse/toxic effect of Antimalarial Agents. Management: Artemether/Lumefantrine (combination product) should not be used with other antimalarials unless there is no other treatment option.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carvedilol: CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Carvedilol. Specifically, concentrations of the S-carvedilol enantiomer may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Substrates: CYP2C9 Inhibitors (Moderate) may decrease the metabolism of CYP2C9 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dapsone (Systemic): Antimalarial Agents may enhance the adverse/toxic effect of Dapsone (Systemic). Specifically, concomitant use of antimalarial agents with dapsone may increase the risk of hemolytic reactions. Dapsone (Systemic) may enhance the adverse/toxic effect of Antimalarial Agents. Specifically, concomitant use of dapsone with antimalarial agents may increase the risk for hemolytic reactions.  Management: Closely monitor patients for signs/symptoms of hemolytic reactions with concomitant use of dapsone and antimalarial agents, particularly in patients deficient in glucose-6-phosphate dehydrogenase (G6PD), methemoglobin reductase, or with hemoglobin M.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dapsone (Topical): Antimalarial Agents may enhance the adverse/toxic effect of Dapsone (Topical). Specifically, the risk of hemolytic reactions may be increased.  Management: Closely monitor for signs/symptoms of hemolytic reactions with concomitant use of topical dapsone and antimalarial agents. Patients with glucose-6-phosphate dehydrogenase deficiency may be at particularly high risk for adverse hematologic effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lumefantrine: Antimalarial Agents may enhance the adverse/toxic effect of Lumefantrine.  Management: Artemether/Lumefantrine (combination product) should not be used with other antimalarials unless there is no other treatment option.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylfolate: May diminish the therapeutic effect of Pyrimethamine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F216063\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F216078\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects have been observed in animal reproduction studies. If administered during pregnancy (ie, for toxoplasmosis), supplementation of folate is strongly recommended. Pregnancy should be avoided during therapy.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F216103\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended (AAP rates &ldquo;compatible&rdquo;; AAP 2001 update pending)",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F216079\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Pyrimethamine enters breast milk and may result in significant systemic concentrations in breast-fed infants. The effect of concurrent therapy with sulfonamide or dapsone (frequently used with pyrimethamine as combination treatment) must be considered.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F9603935\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Take with meals to minimize GI distress.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F216077\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Daraprim Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg (100): $1414.42",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F216065\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC, including platelet counts",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F216080\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Daraprim (AE, AR, AT, AU, BB, BE, BF, BG, BH, BJ, BM, BS, BZ, CH, CI, CN, CY, CZ, DE, EG, ES, ET, GB, GH, GM, GN, GR, GY, HK, IE, IL, IN, IQ, IR, JM, JO, KE, KP, KW, LB, LR, LU, LY, MA, ML, MR, MU, MW, MX, NE, NG, NL, NO, OM, PE, PL, QA, SA, SC, SD, SL, SN, SR, SY, TN, TT, TW, TZ, UG, UY, YE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Daraprin (BR);",
"     </li>",
"     <li>",
"      Malocide (FR);",
"     </li>",
"     <li>",
"      Tindurin (HN, HU);",
"     </li>",
"     <li>",
"      Toxopirin (DO)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F216055\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits parasitic dihydrofolate reductase, resulting in inhibition of vital tetrahydrofolic acid synthesis",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F216073\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: ~1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Well absorbed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Widely, mainly in blood cells, kidneys, lungs, liver, and spleen; crosses into CSF",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 80% to 87%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 80-95 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: 1.5-8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (20% to 30% as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"Transfer of Drugs and Other Chemicals Into Human Milk,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/51/23350/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Akinyanju O, Goddell JC, and Ahmed I, &ldquo;Pyrimethamine Poisoning,&rdquo;",
"      <i>",
"       Br Med J",
"      </i>",
"      , 1973, 4(885):147-8.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention, &ldquo;Guidelines for the Prevention and Treatment of Opportunistic Infections Among HIV-Exposed and HIV-Infected Children: Recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2009, 58(RR-11):1-166. Available at",
"      <a href=\"file://aidsinfo.nih.gov/contentfiles/Pediatric_OI.pdf\" target=\"_blank\">",
"       file://aidsinfo.nih.gov/contentfiles/Pediatric_OI.pdf",
"      </a>",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/51/23350/abstract-text/19730409/pubmed\" id=\"19730409\" target=\"_blank\">",
"        19730409",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention, &ldquo;Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents: Recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2009, 58(RR-4):1-207.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/51/23350/abstract-text/19357635/pubmed\" id=\"19357635\" target=\"_blank\">",
"        19357635",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chute JP, Decker CF, and Cotelingam J, &ldquo;Severe Megaloblastic Anemia Complicating Pyrimethamine Therapy,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 1995, 122(11):884-5.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Drugs for Parasitic Infections,&rdquo;",
"      <i>",
"       Med Lett Drugs Ther",
"      </i>",
"      , 2002. Available at  file://www.medicalletter.com/freedocs/parasitic.pdf",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/51/23350/abstract-text/8544792/pubmed\" id=\"8544792\" target=\"_blank\">",
"        8544792",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Katlama C, De Wit S, O'Doherty E, et al, &ldquo;Pyrimethamine-Clindamycin vs Pyrimethamine-Sulfadiazine as Acute and Long-Term Therapy for Toxoplasmic Encephalitis in Patients With AIDS,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 1996, 22(2):268-75.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/51/23350/abstract-text/8838183/pubmed\" id=\"8838183\" target=\"_blank\">",
"        8838183",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Phillips-Howard PA and West LJ, &ldquo;Serious Adverse Drug Reactions to Pyrimethamine-Sulfadoxine, Pyrimethamine-Dapsone, and to Amodiaquine in Britain,&rdquo;",
"      <i>",
"       J R Soc Med",
"      </i>",
"      , 1990, 83(2):82-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/51/23350/abstract-text/2138674/pubmed\" id=\"2138674\" target=\"_blank\">",
"        2138674",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Porter SB and Sande MA, &ldquo;Toxoplasmosis of the Central Nervous System in the Acquired Immunodeficiency Syndrome,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1992, 327(23):1643-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/51/23350/abstract-text/1359410/pubmed\" id=\"1359410\" target=\"_blank\">",
"        1359410",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Torre D, Casari S, Speranza F, et al, &ldquo;Randomized Trial of Trimethoprim-Sulfamethoxazole Versus Pyrimethamine-Sulfadiazine for Therapy of Toxoplasmic Encephalitis in Patients With AIDS. Italian Collaborative Study Group,&rdquo;",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 1998, 42(6):1346-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/51/23350/abstract-text/9624473/pubmed\" id=\"9624473\" target=\"_blank\">",
"        9624473",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Van Voorhis WC, &ldquo;Therapy and Prophylaxis of Systemic Protozoan Infections,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 1990, 40(2):176-202.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/51/23350/abstract-text/2121456/pubmed\" id=\"2121456\" target=\"_blank\">",
"        2121456",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      White NJ, &ldquo;Clinical Pharmacokinetics of Antimalarial Drugs,&rdquo;",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 1985, 10(3):187-215.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/51/23350/abstract-text/3893840/pubmed\" id=\"3893840\" target=\"_blank\">",
"        3893840",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      World Health Organization, &ldquo;Guidelines for the Treatment of Malaria,&rdquo; 2010, World Health Organization, Geneva. Available at file://whqlibdoc.who.int/publications/2010/9789241547925_eng.pdf",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9841 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-61.234.146.186-B09A38F648-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_51_23350=[""].join("\n");
var outline_f22_51_23350=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216093\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216094\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216127\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216098\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216114\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216099\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216067\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216052\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216070\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216068\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216134\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216125\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216074\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216056\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216123\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216061\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216063\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216078\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216103\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216079\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9603935\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216077\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216065\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216080\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216055\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216073\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9841\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9841|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?9/12/9413?source=related_link\">",
"      Pyrimethamine: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/50/7973?source=related_link\">",
"      Pyrimethamine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_51_23351="Magnetic resonance cholangiopancreatography";
var content_f22_51_23351=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Magnetic resonance cholangiopancreatography",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/51/23351/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/51/23351/contributors\">",
"     Umaprasanna S Karnam, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/51/23351/contributors\">",
"     Jonathan B Kruskal, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/51/23351/contributors\">",
"     K Rajender Reddy, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/51/23351/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/51/23351/contributors\">",
"     Douglas A Howell, MD, FASGE, FACG",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/51/23351/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/51/23351/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/51/23351/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 12, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Magnetic resonance cholangiopancreatography (MRCP) is a noninvasive technique for evaluating the intrahepatic and extrahepatic bile ducts and the pancreatic duct [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23351/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TECHNIQUE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unlike conventional endoscopic retrograde cholangiopancreatography (ERCP), MRCP does not require contrast material to be administered into the ductal system. Thus, the morbidity associated with endoscopic procedures and contrast materials is avoided. However, MRCP does not currently allow any intervention to be performed, such as stone extraction, stent insertion, or biopsy.",
"   </p>",
"   <p>",
"    Since the introduction of MRCP in 1991, technological refinements have made it an extremely useful modality in the evaluation of the hepatobiliary tree. The technique was initially performed with the use of heavily T2-weighted MR pulse sequences. These had the effect of making stationary or slow-flowing fluid within the bile and pancreatic ducts to appear very bright relative to the low signal intensity produced by adjacent solid tissues [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23351/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. With the specific image acquisition sequences used, flowing blood had little or no measurable signal; as a result, blood vessels were not mistaken for bile or pancreatic ducts. The ducts could be visualized from multiple projections, thereby duplicating cholangiographic images noninvasively.",
"   </p>",
"   <p>",
"    However, this method was limited in its ability to detect non-dilated bile ducts because of a low signal-to-noise ratio, and sensitivity to motion artifacts. Newer variants of MR including the rapid acquisition with relaxation enhancement (RARE) and half-Fourier acquisition single-shot turbo spin-echo (HASTE) provide superior images. Single-shot RARE and HASTE techniques can be performed in a breath-hold period with a scan time of &lt;20 seconds.",
"   </p>",
"   <p>",
"    The optimal protocol to perform MRCP has not been defined and there continues to be variation across centers. As a general rule, the protocol depends upon the specific MR magnet being used, including its field strength (eg 1.5 versus 3T) and the manufacturer, as well as institutional experience and preferences. However, all acquisition protocols obtain heavily T2-weighted images as thick slabs and the images are reformatted in planes to optimize depiction of the extrahepatic ducts. Volume-rendered images may be used to depict the intra- and extrahepatic bile ducts.",
"   </p>",
"   <p>",
"    A newer technique to minimize signal from the stomach and duodenum, and thus increase the visibility of the biliary tree, has been the administration of a single dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/56/42888?source=see_link\">",
"     ranitidine",
"    </a>",
"    300 mg two to three hours prior to the study [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23351/abstract/5\">",
"     5",
"    </a>",
"    ]. In addition, one report found that intravenous glucagon improved visualization of the common bile duct and ampulla of Vater during MRCP without any documented adverse effects [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23351/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Limitations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The main potential problems with MRCP are image artifacts and difficulty in patient compliance. Image artifacts can be produced by a bright signal arising from stationary fluid within the adjacent duodenum, duodenal diverticulae, and ascitic fluid. In addition, local areas of dropout of signal can be caused by metallic clips following cholecystectomy, crossing defects induced by the right hepatic artery, or from severely narrowed ducts, such as occurs with primary sclerosing cholangitis (PSC). The presence of metal leads or fragments precludes any MR imaging study. Other problems which can erroneously suggest common bile duct obstruction or common bile duct stones are discussed in the appropriate sections below.",
"   </p>",
"   <p>",
"    Currently, MRCP has lower resolution than direct cholangiography and can miss small stones (&lt;4 mm), small ampullary lesions, primary sclerosing cholangitis, and strictures of the ducts. MRCP also has difficulty visualizing small stones in the pancreatic duct. In addition, as will be mentioned below, certain anatomic characteristics or disorders can mimic bile duct obstruction or common bile duct stones. Obstructing stones are generally easier to identify than nonobstructing stones (especially if smaller than the thickness of the acquired image slices). Small stones may not be distinguishable from sludge, mucin, or even blood.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL USE",
"    </span>",
"    &nbsp;&mdash;&nbsp;MRCP provides accurate depiction and measurements of the bile and pancreatic ducts in 95 percent of examinations; associated anatomic variants, such as pancreas divisum and choledochal cysts, and pancreatic ductal disruptions can also be visualized [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23351/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. The technique is useful for documenting communication between pancreatic cysts and ducts, and for evaluating the nature of pancreatic cysts. However, since it is fluid within ducts that is depicted, MRCP cannot differentiate between focal strictures and spasm of the common bile duct.",
"   </p>",
"   <p>",
"    The following sections will briefly describe some of the major clinical uses of MRCP in patients with suspected hepatobiliary disease. The use of MRCP and other imaging studies in the individual disorders is discussed in detail on the appropriate topic reviews.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Bile duct obstruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;MRCP can identify the larger intrahepatic ducts and the extrahepatic ducts in 83 to 100 percent of patients with normal caliber ducts [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23351/abstract/7-9\">",
"     7-9",
"    </a>",
"    ]. It has a greater ability to depict abnormal dilated ducts, and provides diagnostic cholangiogram in 90 to 100 percent of patients; it also reveals the level of obstruction in 80 to 100 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23351/abstract/10-14\">",
"     10-14",
"    </a>",
"    ], and may have a role in the diagnosis of postcholecystectomy biliary complications [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23351/abstract/15\">",
"     15",
"    </a>",
"    ]. A systematic review that included a total of 67 studies found that the overall sensitivity and specificity of MRCP for the diagnosis of biliary obstruction were 95 and 97 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23351/abstract/16\">",
"     16",
"    </a>",
"    ]. Sensitivity was lower for stones (92 percent) and for malignant conditions (88 percent). In a prospective double-blind study MRCP had a high sensitivity, but lower specificity for identifying post-transplant biliary strictures [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23351/abstract/17\">",
"     17",
"    </a>",
"    ]. However, MRCP is a passive anatomic technique that does not display functional information, such as the degree of obstruction to flow, which can be seen by conventional cholangiography.",
"   </p>",
"   <p>",
"    There are some technical pitfalls that can interfere with the interpretation of MRCP in bile duct obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23351/abstract/18\">",
"     18",
"    </a>",
"    ]. As an example, low union of the cystic duct with the common hepatic duct with both ducts running in parallel for a significant distance may result in a combined image suggestive of common bile duct dilation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Cholangiocarcinoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once ductal dilation is established by ultrasonography, the next step has been to fully image the biliary tree via ERCP or percutaneous transhepatic cholangiography (PTC). These invasive procedures can exclude choledocholithiasis and define the location and extent of the biliary lesion. ERCP remains preferred in patients with primary sclerosing cholangitis (a major predisposing factor to cholangiocarcinoma). Conversely, PTC was formerly preferred to image the more proximal biliary system if complete obstruction of the distal biliary tree is suspected.",
"   </p>",
"   <p>",
"    The role of MRCP in the diagnosis and management of bile duct malignancy is not yet defined. It will probably prove to be a useful noninvasive adjunct to present techniques, since it has the capability to evaluate the bile ducts both above and below a stricture while also identifying any intrahepatic mass lesions (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef73964 \" href=\"UTD.htm?9/47/9968\">",
"     image 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef72880 \" href=\"UTD.htm?13/6/13423\">",
"     image 2",
"    </a>",
"    ). One series evaluated MRCP in 126 patients with suspected bile duct obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23351/abstract/11\">",
"     11",
"    </a>",
"    ]. Fourteen had malignant obstruction that was diagnosed by MRCP in 12; the positive predictive value was 86 percent and the negative predictive value 98 percent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/43/40633?source=see_link\">",
"     \"Clinical manifestations and diagnosis of cholangiocarcinoma\"",
"    </a>",
"    .) In other reports, MRCP alone had limited specificity in the diagnosis of malignant strictures [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23351/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Malignant hilar and perihilar obstruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;MRCP appears to be useful in delineating the anatomical extent of perihilar obstruction and interpreting its etiology. One study, for example, included 40 patients with malignant perihilar biliary obstruction who underwent ERCP and MRCP [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23351/abstract/20\">",
"     20",
"    </a>",
"    ]. Both tests were equally effective in detecting the biliary obstruction. However, MRCP was superior in the investigation of the anatomical extent and the type of tumor. Similar conclusions have been reached in other reports [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23351/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Patients with known or suspected PSC",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with known or suspected PSC, MRCP is performed along with routine MR images to document the segmental extent of ductal involvement to help plan for surgery, search for intrahepatic metastases, and identify aberrant ductal anatomy. Routine MR images are obtained to document the extent of extrahepatic involvement, including nodes at the porta hepatis.",
"   </p>",
"   <p>",
"    Characteristic changes of PSC are visible on MRCP (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef69476 \" href=\"UTD.htm?8/7/8306\">",
"     image 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23351/abstract/22-25\">",
"     22-25",
"    </a>",
"    ]. However, MRCP provides less spatial resolution than ERCP and lower sensitivity for detecting subtle peripheral ductal abnormalities in the liver. Peripheral ducts may not be visualized because imaging is performed when ducts are in their physiologic, nondistended state. In addition, the subtle mural irregularities see on ERCP may not be detected with MRCP. Furthermore, MRCP does not permit therapeutic intervention. The accuracy of MRCP for diagnosis or screening of cholangiocarcinoma in patients with PSC has not been well established.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Common duct stones",
"    </span>",
"    &nbsp;&mdash;&nbsp;Common duct stones (choledocholithiasis) are readily displayed by MRCP as a signal void within the bright signal arising from bile (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef68692 \" href=\"UTD.htm?27/47/28403\">",
"     image 4",
"    </a>",
"    ). Multiple studies have compared test characteristics of MRCP with other imaging modalities in detection of choledocholithiasis. As a general rule, test characteristics of MRCP appear to be similar to ERCP for detecting choledocholithiasis (sensitivity 80 to 100 percent, specificity 85 to 100 percent) (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef80729 \" href=\"UTD.htm?20/28/20943\">",
"     image 5",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23351/abstract/11-14,22,26-28\">",
"     11-14,22,26-28",
"    </a>",
"    ]. In an illustrative study (involving 32 patients with suspected biliary pancreatitis), the sensitivity of transabdominal ultrasonography, CT, MRCP, ERCP and intraductal ultrasonography was 20, 40, 80, 90, and 95 percent, respectively compared with ERCP plus stone extraction as the reference standard [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23351/abstract/29\">",
"     29",
"    </a>",
"    ]. The overall agreement between MRCP and ERCP was 91 percent.",
"   </p>",
"   <p>",
"    However, as noted above, test characteristics depend in part upon the imaging techniques, experience, size of the stone, and anatomy surrounding biliary tree. Sensitivity of MRCP decreased with dilated bile ducts (73 percent for a bile duct diameter &gt;10 mm versus 89 percent for small diameter bile ducts) in one of the reports above [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23351/abstract/29\">",
"     29",
"    </a>",
"    ]. In the presence of a dilated CBD, MRCP has a 90 to 95 percent concordance with ERCP in diagnosing CBD stones over 4 mm in diameter [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23351/abstract/26,27\">",
"     26,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Stones larger than 4 mm are readily seen but cannot be differentiated from filling defects such as blood clots, tumor, sludge, or parasites [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23351/abstract/30\">",
"     30",
"    </a>",
"    ]. Other mimickers of choledocholithiasis include flow artifacts, biliary air, and a pseudostone at the ampulla [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23351/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The choice of procedure varies with the clinical setting and local availability. In patients with cholangitis, for example, ERCP is preferred because it permits therapeutic drainage of the obstruction. However, MRCP may be performed if cholangitis is not severe and the risks of ERCP are high. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/13/24790?source=see_link\">",
"     \"Acute cholangitis\"",
"    </a>",
"    .) MRCP may also be useful after unsuccessful or incomplete ERCP and in imaging the CBD in patients undergoing laparoscopic cholecystectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23351/abstract/31\">",
"     31",
"    </a>",
"    ]. Endoscopic ultrasound may also be an option in individuals considered at increased risk for ERCP. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/34/43557?source=see_link\">",
"     \"Endoscopic ultrasound in patients with suspected choledocholithiasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Acute cholecystitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of MRCP for the diagnosis of acute cholecystitis was evaluated in a series that included 35 patients with symptoms of acute cholecystitis who underwent both ultrasound and MR cholangiography prior to cholecystectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23351/abstract/32\">",
"     32",
"    </a>",
"    ]. MRCP was superior to ultrasound for detecting stones in the cystic duct (sensitivity 100 versus 14 percent) but was less sensitive than ultrasound for detecting gallbladder wall thickening (sensitivity 69 versus 96 percent). At the present time its role in the diagnosis of acute cholecystitis should remain within clinical trials. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/33/29208?source=see_link\">",
"     \"Pathogenesis, clinical features, and diagnosis of acute cholecystitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Pancreatitis and pancreatic cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;MRCP has been evaluated in both acute and chronic pancreatitis. In patients with acute pancreatitis, MRCP is useful for evaluating the bile ducts and cystic duct remnants for stones, for evaluating the pancreatic ducts, and for documenting the presence of cysts in or around the pancreas [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23351/abstract/33\">",
"     33",
"    </a>",
"    ]. However, ERCP is often preferred in patients with gallstone pancreatitis since endoscopic papillotomy performed during the same procedure may be beneficial in patients with obstructive jaundice (with a serum bilirubin concentration above 5",
"    <span class=\"nowrap\">",
"     mg/dL)",
"    </span>",
"    or biliary sepsis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/35/7738?source=see_link&amp;anchor=H14#H14\">",
"     \"Treatment of acute pancreatitis\", section on 'Gallstone pancreatitis'",
"    </a>",
"    .) In patients with failed ERCP and in those with biliary-enteric anastomoses with which ERCP may be contraindicated, MRCP can be used to image the ducts and evaluate the anastomosis, respectively.",
"   </p>",
"   <p>",
"    MRCP can also detect pancreas divisum [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23351/abstract/34\">",
"     34",
"    </a>",
"    ]. However, the possible association of this variant with the development of either acute or chronic pancreatitis remains controversial. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/61/14297?source=see_link&amp;anchor=H17#H17\">",
"     \"Etiology of acute pancreatitis\", section on 'Pancreas divisum'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/41/39575?source=see_link\">",
"     \"Etiology and pathogenesis of chronic pancreatitis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    MRCP appears to be as accurate as ERCP for distinguishing pancreatic cancer from chronic pancreatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23351/abstract/35\">",
"     35",
"    </a>",
"    ]. This was illustrated in a prospective study involving 124 patients who were suspected of having pancreatic cancer and underwent a number of diagnostic studies, including ERCP and MRCP. The correct diagnosis was confirmed histologically and clinically. A diagnosis of pancreatic cancer was established in 37 patients (30 percent); the others had chronic pancreatitis (46 percent) or other causes. The sensitivity and specificity of MRCP for diagnosing pancreatic cancer were 84 and 97 percent, which was similar to ERCP 70 and 94 percent, respectively.",
"   </p>",
"   <p>",
"    MRCP has also been used for surveillance in patients with mutations that predispose to pancreatic cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23351/abstract/36\">",
"     36",
"    </a>",
"    ]. In a study of 79 patients with a p16-Leiden mutation who were followed for a median of four years, pancreatic cancer was detected in seven patients (9 percent). Possible cancer precursors were detected in an additional nine patients (11 percent). All of the patients with pancreatic cancer had resectable lesions.",
"   </p>",
"   <p>",
"    MRCP may have advantages compared to ERCP in specific settings such as in patients who have gastric outlet or duodenal stenosis or who have had surgical rearrangement (eg, Billroth II) or ductal disruption, resulting in ducts which cannot be assessed by ERCP. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/13/30935?source=see_link\">",
"     \"Clinical manifestations and diagnosis of chronic pancreatitis in adults\"",
"    </a>",
"    .) It can also be used to detect bile duct obstruction occurring as a complication of chronic pancreatitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/47/35572?source=see_link\">",
"     \"Complications of chronic pancreatitis\"",
"    </a>",
"    .) Post-ERCP pancreatitis correlates with the extent of pancreatic ductal filling further underscoring an advantage of MRCP for pancreatic ductal imaging [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23351/abstract/37\">",
"     37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/63/28666?source=see_link\">",
"     \"Post-ERCP pancreatitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2843337\">",
"    <span class=\"h2\">",
"     Pancreatic duct disruption",
"    </span>",
"    &nbsp;&mdash;&nbsp;Causes of pancreatic duct disruption include acute and chronic pancreatitis, blunt or penetrating trauma, and complications of surgical procedures such as splenectomy. MRCP may be a particularly attractive option in patients following traumatic injury when performance of ERCP may not be possible. Findings suggestive of a pancreatic duct disruption on MRCP include ductal dilation proximal to the disruption, focal interruption of duct continuity, apparent communication of the duct with fluid collections, and pancreatic fracture involving the pancreatic duct [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23351/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. In addition to aiding with the diagnosis of pancreatic duct disruption, MRCP can also be used to follow-up patients who are managed conservatively [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23351/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a small retrospective series that used ERCP as the gold-standard for diagnosing a ductal disruption, MRCP correctly identified 21 of 23 patients with a ductal disruption (91 percent sensitivity) and 8 of 8 patients with an intact duct (100 percent specificity) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23351/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H65081352\">",
"    <span class=\"h2\">",
"     Secretin-enhanced MRCP",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/49/28435?source=see_link\">",
"     Secretin",
"    </a>",
"    -enhanced MRCP is being increasingly studied for evaluation of pancreatic exocrine function and in the early diagnosis of chronic pancreatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23351/abstract/41-47\">",
"     41-47",
"    </a>",
"    ]. It is used most commonly in patients with chronic pancreatitis, a setting in which it can help characterize subtle pancreatic disease by improving the depiction of the pancreatic duct anatomy. Secretin stimulation is not used for imaging bile ducts.",
"   </p>",
"   <p>",
"    One study of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/49/28435?source=see_link\">",
"     secretin",
"    </a>",
"    -enhanced MRCP included 25 consecutive patients with persistently elevated pancreatic enzymes but no symptoms and compared the findings with those in age-matched controls [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23351/abstract/48\">",
"     48",
"    </a>",
"    ]. Ductal changes of chronic pancreatitis were seen in 13 of 25 patients (52 percent) with elevated pancreatic enzymes. None of the studies were considered abnormal in the control patients. However, there is significant additional cost associated with secretin-enhanced MRCP, so confirmation of the test's diagnostic accuracy in this and other settings of suspected early chronic pancreatitis is needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Magnetic resonance cholangiopancreatography (MRCP) is a noninvasive technique for evaluating the intrahepatic and extrahepatic bile ducts and the pancreatic duct.",
"     </li>",
"     <li>",
"      Unlike conventional endoscopic retrograde cholangiopancreatography (ERCP), MRCP does not require contrast material to be administered into the ductal system. Thus, the morbidity associated with endoscopic procedures and contrast materials is avoided. However, MRCP does not currently allow any intervention to be performed, such as stone extraction, stent insertion, or biopsy. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Technique'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The accuracy of MRCP and its clinical role depend upon the clinical setting. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical use'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/49/28435?source=see_link\">",
"       Secretin",
"      </a>",
"      -enhanced MRCP may increase sensitivity in the diagnosis of early chronic pancreatitis. (See",
"      <a class=\"local\" href=\"#H65081352\">",
"       'Secretin-enhanced MRCP'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23351/abstract/1\">",
"      Barish MA, Yucel EK, Ferrucci JT. Magnetic resonance cholangiopancreatography. N Engl J Med 1999; 341:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23351/abstract/2\">",
"      Reinhold C, Bret PM. Current status of MR cholangiopancreatography. AJR Am J Roentgenol 1996; 166:1285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23351/abstract/3\">",
"      Bret PM, Reinhold C. Magnetic resonance cholangiopancreatography. Endoscopy 1997; 29:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23351/abstract/4\">",
"      Wallner BK, Schumacher KA, Weidenmaier W, Friedrich JM. Dilated biliary tract: evaluation with MR cholangiography with a T2-weighted contrast-enhanced fast sequence. Radiology 1991; 181:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23351/abstract/5\">",
"      Bowes MT, Martin DF, Melling A, et al. Single dose oral ranitidine improves MRCP image quality: a double-blind study. Clin Radiol 2007; 62:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23351/abstract/6\">",
"      Dalal PU, Howlett DC, Sallomi DF, et al. Does intravenous glucagon improve common bile duct visualisation during magnetic resonance cholangiopancreatography? Results in 42 patients. Eur J Radiol 2004; 49:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23351/abstract/7\">",
"      Miyazaki T, Yamashita Y, Tsuchigame T, et al. MR cholangiopancreatography using HASTE (half-Fourier acquisition single-shot turbo spin-echo) sequences. AJR Am J Roentgenol 1996; 166:1297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23351/abstract/8\">",
"      Hintze RE, Adler A, Veltzke W, et al. Clinical significance of magnetic resonance cholangiopancreatography (MRCP) compared to endoscopic retrograde cholangiopancreatography (ERCP). Endoscopy 1997; 29:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23351/abstract/9\">",
"      Taylor AC, Little AF, Hennessy OF, et al. Prospective assessment of magnetic resonance cholangiopancreatography for noninvasive imaging of the biliary tree. Gastrointest Endosc 2002; 55:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23351/abstract/10\">",
"      Hall-Craggs MA, Allen CM, Owens CM, et al. MR cholangiography: clinical evaluation in 40 cases. Radiology 1993; 189:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23351/abstract/11\">",
"      Guibaud L, Bret PM, Reinhold C, et al. Bile duct obstruction and choledocholithiasis: diagnosis with MR cholangiography. Radiology 1995; 197:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23351/abstract/12\">",
"      Becker CD, Grossholz M, Becker M, et al. Choledocholithiasis and bile duct stenosis: diagnostic accuracy of MR cholangiopancreatography. Radiology 1997; 205:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23351/abstract/13\">",
"      Lomanto D, Pavone P, Laghi A, et al. Magnetic resonance-cholangiopancreatography in the diagnosis of biliopancreatic diseases. Am J Surg 1997; 174:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23351/abstract/14\">",
"      Varghese JC, Farrell MA, Courtney G, et al. A prospective comparison of magnetic resonance cholangiopancreatography with endoscopic retrograde cholangiopancreatography in the evaluation of patients with suspected biliary tract disease. Clin Radiol 1999; 54:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23351/abstract/15\">",
"      Coakley FV, Schwartz LH, Blumgart LH, et al. Complex postcholecystectomy biliary disorders: preliminary experience with evaluation by means of breath-hold MR cholangiography. Radiology 1998; 209:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23351/abstract/16\">",
"      Romagnuolo J, Bardou M, Rahme E, et al. Magnetic resonance cholangiopancreatography: a meta-analysis of test performance in suspected biliary disease. Ann Intern Med 2003; 139:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23351/abstract/17\">",
"      Chard PS, Qayyum A, Mein S, et al. Magnetic resonance cholangiopancreatography for the noninvasive evaluation of liver transplant patients with suspected biliary strictures: A prospective Double-blind study. Gastroenterology 2004; 126:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23351/abstract/18\">",
"      David V, Reinhold C, Hochman M, et al. Pitfalls in the interpretation of MR cholangiopancreatography. AJR Am J Roentgenol 1998; 170:1055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23351/abstract/19\">",
"      R&ouml;sch T, Meining A, Fr&uuml;hmorgen S, et al. A prospective comparison of the diagnostic accuracy of ERCP, MRCP, CT, and EUS in biliary strictures. Gastrointest Endosc 2002; 55:870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23351/abstract/20\">",
"      Yeh TS, Jan YY, Tseng JH, et al. Malignant perihilar biliary obstruction: magnetic resonance cholangiopancreatographic findings. Am J Gastroenterol 2000; 95:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23351/abstract/21\">",
"      Lopera JE, Soto JA, M&uacute;nera F. Malignant hilar and perihilar biliary obstruction: use of MR cholangiography to define the extent of biliary ductal involvement and plan percutaneous interventions. Radiology 2001; 220:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23351/abstract/22\">",
"      Fulcher AS, Turner MA, Capps GW, et al. Half-Fourier RARE MR cholangiopancreatography: experience in 300 subjects. Radiology 1998; 207:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23351/abstract/23\">",
"      Ernst O, Asselah T, Sergent G, et al. MR cholangiography in primary sclerosing cholangitis. AJR Am J Roentgenol 1998; 171:1027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23351/abstract/24\">",
"      Vitellas KM, Keogan MT, Freed KS, et al. Radiologic manifestations of sclerosing cholangitis with emphasis on MR cholangiopancreatography. Radiographics 2000; 20:959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23351/abstract/25\">",
"      Elsayes KM, Oliveira EP, Narra VR, et al. MR and MRCP in the evaluation of primary sclerosing cholangitis: current applications and imaging findings. J Comput Assist Tomogr 2006; 30:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23351/abstract/26\">",
"      Chan YL, Chan AC, Lam WW, et al. Choledocholithiasis: comparison of MR cholangiography and endoscopic retrograde cholangiography. Radiology 1996; 200:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23351/abstract/27\">",
"      Lee MG, Lee HJ, Kim MH, et al. Extrahepatic biliary diseases: 3D MR cholangiopancreatography compared with endoscopic retrograde cholangiopancreatography. Radiology 1997; 202:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23351/abstract/28\">",
"      Varghese JC, Liddell RP, Farrell MA, et al. Diagnostic accuracy of magnetic resonance cholangiopancreatography and ultrasound compared with direct cholangiography in the detection of choledocholithiasis. Clin Radiol 2000; 55:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23351/abstract/29\">",
"      Moon JH, Cho YD, Cha SW, et al. The detection of bile duct stones in suspected biliary pancreatitis: comparison of MRCP, ERCP, and intraductal US. Am J Gastroenterol 2005; 100:1051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23351/abstract/30\">",
"      Barish MA, Yucel EK, Soto JA, et al. MR cholangiopancreatography: efficacy of three-dimensional turbo spin-echo technique. AJR Am J Roentgenol 1995; 165:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23351/abstract/31\">",
"      Soto JA, Yucel EK, Barish MA, et al. MR cholangiopancreatography after unsuccessful or incomplete ERCP. Radiology 1996; 199:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23351/abstract/32\">",
"      Park MS, Yu JS, Kim YH, et al. Acute cholecystitis: comparison of MR cholangiography and US. Radiology 1998; 209:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23351/abstract/33\">",
"      Soto JA, Barish MA, Yucel EK, et al. Pancreatic duct: MR cholangiopancreatography with a three-dimensional fast spin-echo technique. Radiology 1995; 196:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23351/abstract/34\">",
"      Bret PM, Reinhold C, Taourel P, et al. Pancreas divisum: evaluation with MR cholangiopancreatography. Radiology 1996; 199:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23351/abstract/35\">",
"      Adamek HE, Albert J, Breer H, et al. Pancreatic cancer detection with magnetic resonance cholangiopancreatography and endoscopic retrograde cholangiopancreatography: a prospective controlled study. Lancet 2000; 356:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23351/abstract/36\">",
"      Vasen HF, Wasser M, van Mil A, et al. Magnetic resonance imaging surveillance detects early-stage pancreatic cancer in carriers of a p16-Leiden mutation. Gastroenterology 2011; 140:850.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23351/abstract/37\">",
"      Cheon YK, Cho KB, Watkins JL, et al. Frequency and severity of post-ERCP pancreatitis correlated with extent of pancreatic ductal opacification. Gastrointest Endosc 2007; 65:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23351/abstract/38\">",
"      Soto JA, Alvarez O, M&uacute;nera F, et al. Traumatic disruption of the pancreatic duct: diagnosis with MR pancreatography. AJR Am J Roentgenol 2001; 176:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23351/abstract/39\">",
"      Rekhi S, Anderson SW, Rhea JT, Soto JA. Imaging of blunt pancreatic trauma. Emerg Radiol 2010; 17:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23351/abstract/40\">",
"      Drake LM, Anis M, Lawrence C. Accuracy of magnetic resonance cholangiopancreatography in identifying pancreatic duct disruption. J Clin Gastroenterol 2012; 46:696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23351/abstract/41\">",
"      Czak&oacute; L, Endes J, Tak&aacute;cs T, et al. Evaluation of pancreatic exocrine function by secretin-enhanced magnetic resonance cholangiopancreatography. Pancreas 2001; 23:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23351/abstract/42\">",
"      De Vitis I, Spada C, Manfredi R, et al. Morpho-functional evaluation of chronic pancreatitis in early phases with MRCP after Secretin stimulation. Gastroenterology 2001; 120:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23351/abstract/43\">",
"      Manfredi R, Costamagna G, Brizi MG, et al. Severe chronic pancreatitis versus suspected pancreatic disease: dynamic MR cholangiopancreatography after secretin stimulation. Radiology 2000; 214:849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23351/abstract/44\">",
"      Czak&oacute; L, Tak&aacute;cs T, Morvay Z, et al. Diagnostic role of secretin-enhanced MRCP in patients with unsuccessful ERCP. World J Gastroenterol 2004; 10:3034.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23351/abstract/45\">",
"      Mariani A, Curioni S, Zanello A, et al. Secretin MRCP and endoscopic pancreatic manometry in the evaluation of sphincter of Oddi function: a comparative pilot study in patients with idiopathic recurrent pancreatitis. Gastrointest Endosc 2003; 58:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23351/abstract/46\">",
"      Fukukura Y, Fujiyoshi F, Sasaki M, Nakajo M. Pancreatic duct: morphologic evaluation with MR cholangiopancreatography after secretin stimulation. Radiology 2002; 222:674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23351/abstract/47\">",
"      Testoni PA, Mariani A, Curioni S, et al. MRCP-secretin test-guided management of idiopathic recurrent pancreatitis: long-term outcomes. Gastrointest Endosc 2008; 67:1028.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23351/abstract/48\">",
"      Testoni PA, Mariani A, Curioni S, et al. Pancreatic ductal abnormalities documented by secretin-enhanced MRCP in asymptomatic subjects with chronic pancreatic hyperenzymemia. Am J Gastroenterol 2009; 104:1780.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 664 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-61.234.146.186-7727F3B860-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_51_23351=[""].join("\n");
var outline_f22_51_23351=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TECHNIQUE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Limitations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL USE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Bile duct obstruction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Cholangiocarcinoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Malignant hilar and perihilar obstruction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Patients with known or suspected PSC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Common duct stones",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Acute cholecystitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Pancreatitis and pancreatic cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2843337\">",
"      Pancreatic duct disruption",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H65081352\">",
"      Secretin-enhanced MRCP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/664\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/664|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?9/47/9968\" title=\"diagnostic image 1\">",
"      Cholangiocarcinoma MRCP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?13/6/13423\" title=\"diagnostic image 2\">",
"      Proximal cholangiocarcinoma MRCP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?8/7/8306\" title=\"diagnostic image 3\">",
"      MRCP in a patient with primary sclerosing cholangitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?27/47/28403\" title=\"diagnostic image 4\">",
"      CBD stones MRCP I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?20/28/20943\" title=\"diagnostic image 5\">",
"      CBD stones MRCP II",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/13/24790?source=related_link\">",
"      Acute cholangitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/43/40633?source=related_link\">",
"      Clinical manifestations and diagnosis of cholangiocarcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/13/30935?source=related_link\">",
"      Clinical manifestations and diagnosis of chronic pancreatitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/47/35572?source=related_link\">",
"      Complications of chronic pancreatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/34/43557?source=related_link\">",
"      Endoscopic ultrasound in patients with suspected choledocholithiasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/41/39575?source=related_link\">",
"      Etiology and pathogenesis of chronic pancreatitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/61/14297?source=related_link\">",
"      Etiology of acute pancreatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/33/29208?source=related_link\">",
"      Pathogenesis, clinical features, and diagnosis of acute cholecystitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/63/28666?source=related_link\">",
"      Post-ERCP pancreatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/35/7738?source=related_link\">",
"      Treatment of acute pancreatitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_51_23352="Lipodystrophic syndromes";
var content_f22_51_23352=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Lipodystrophic syndromes",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/51/23352/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/51/23352/contributors\">",
"     Christos Mantzoros, MD, DSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/51/23352/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/51/23352/contributors\">",
"     David M Nathan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/51/23352/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/51/23352/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/51/23352/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 24, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The lipodystrophic syndromes are a heterogeneous group of congenital or acquired disorders characterized by either complete or partial lack of adipose tissue (lipoatrophy) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23352/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. In some of these disorders there is also the apparent accumulation of fat in other regions of the body.",
"   </p>",
"   <p>",
"    The extent of fat loss correlates with the severity of the metabolic abnormalities. Clinically, patients with severe lipodystrophy have severe insulin resistance and a group of unique features, such as severe hyperlipidemia, progressive liver disease, and increased metabolic rate (",
"    <a class=\"graphic graphic_table graphicRef79962 \" href=\"UTD.htm?23/0/23563\">",
"     table 1",
"    </a>",
"    ). Acquired and congenital lipodystrophies may also be associated with proteinuric kidney diseases, and renal biopsy of patients with nephrotic range proteinuria has revealed focal segmental glomerulosclerosis or membranoproliferative glomerulonephritis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23352/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is little understanding of the molecular basis for these disorders, but it is likely that multiple molecular defects are responsible. A widely accepted classification of the various types of lipodystrophies is presented in the table (",
"    <a class=\"graphic graphic_table graphicRef71384 \" href=\"UTD.htm?36/47/37627\">",
"     table 2",
"    </a>",
"    ). Other disorders that need to be differentiated from lipodystrophies are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef66232 \" href=\"UTD.htm?3/41/3739\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The current most prevalent form of lipodystrophy is in patients with HIV infection, and likely related to antiretroviral therapy. HIV-related lipodystrophy is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/36/44617?source=see_link\">",
"     \"Treatment of HIV-associated lipodystrophy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENERALIZED LIPODYSTROPHY",
"    </span>",
"    &nbsp;&mdash;&nbsp;These are rare but clinically striking disorders that may be congenital (Seip-Berardinelli syndrome) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23352/abstract/5,6\">",
"     5,6",
"    </a>",
"    ] or acquired (Lawrence syndrome) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23352/abstract/7\">",
"     7",
"    </a>",
"    ]. Their prevalence has been estimated to be less than one case per one million people.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Congenital generalized lipodystrophy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Congenital generalized lipodystrophy (CGL) is inherited as an autosomal recessive trait, with frequent parental consanguinity. At least three molecularly distinct forms of congenital lipodystrophy have been defined, with the mutations of AGPAT2 and BSCL2 being responsible for 95 percent of reported cases of CGLs [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23352/abstract/8-10\">",
"     8-10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Type 1 CGL (CGL1) is due to AGPAT2 gene mutations. This gene has been mapped to chromosomes 9q34. It encodes the enzyme acyltransferase 1-acylglycerol-3-phosphate O-acyltransferase 2 (AGPAT2), which catalyzes the acylation of lysophosphatidic acid to form phosphatidic acid, a key intermediate in the biosynthesis of triacylglyceride and glycerophospholipids. AGPAT2 mutations are found predominantly in patients of African ancestry.",
"     </li>",
"     <li>",
"      Type 2 CGL (CGL2) is due to BSCL2 gene mutations. This gene is located in chromosome 11q13 and encodes a 398-amino-acid protein called seipin. The BSCL2 gene mutation has been found in patients of European and Middle Eastern origins, but has also been reported as a causative gene in Japanese with CGL. BSCL2 expression is critical for normal adipogenesis in vitro, as cells lacking BSCL2 failed to induce expression of key lipogenic transcription factors, including proxisome-proliferator activated receptor gamma (PPARG),",
"      <span class=\"nowrap\">",
"       CCAAT/enhancer",
"      </span>",
"      binging protein-alpha",
"      <span class=\"nowrap\">",
"       (C/EBP-alpha),",
"      </span>",
"      as well as enzymes AGPAT2, DGAT2, and lipin 1.",
"     </li>",
"     <li>",
"      A third gene mutation has been identified in one individual with CGL who had a homozygous nonsense mutation of CAV-1, probably as a result of a consanguineous union. CAV-1 is located on chromosome 7q31 [",
"      <a class=\"abstract\" href=\"UTD.htm?22/51/23352/abstract/11\">",
"       11",
"      </a>",
"      ]. Its end product, caveolin-1, is a highly conserved 22-KDa protein and a major fatty acid binder on the plasma membranes as well as a crucial component of plasma membrane microdomains known as caveolae. These plasma membrane domains have important roles in regulating signaling pathways and processes such as cell migration, polarization, and proliferation. Mutated function of CAV-1 may lead to lipodystrophy by interfering with lipid handling, lipid droplet formation, and adipocyte differentiation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abnormal appearance due to the absence of subcutaneous fat is noted within the first two years of life, often at or soon after birth. Adipose tissue is almost completely absent from most subcutaneous areas, the abdomen, the thorax, and bone marrow, whereas normal amounts of adipose tissue are present in the orbits, mouth and tongue, palms and soles, scalp, perineum and periarticular regions [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23352/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    During childhood these patients have a voracious appetite, accelerated linear growth, increased metabolic rate, and advanced bone age. The final height is usually normal. Other abnormalities are acanthosis nigricans and protuberant abdomen due to hepatomegaly caused by fatty infiltration of the liver, which can lead to cirrhosis and its complications. Prominent musculature and precocious secondary sexual development may also occur, and some patients have mental retardation (",
"    <a class=\"graphic graphic_figure graphicRef78980 \" href=\"UTD.htm?42/51/43825\">",
"     figure 1",
"    </a>",
"    ).&nbsp;",
"   </p>",
"   <p>",
"    Among the three molecularly distinct forms of CGL, the clinical phenotype varies [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23352/abstract/10,13\">",
"     10,13",
"    </a>",
"    ]. CGL2 due to seipin mutation appears to manifest itself as a more severe disease phenotype than that due to AGPAT2 mutation (CGL1), with a higher incidence of premature death and a lower prevalence of partial",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    delayed onset of lipodystrophy. In addition, compared to CGL1, CGL2 patients have more pronounced absence of body fat, loss of metabolically active fat (subcutaneous regions, intermuscular regions, bone marrow, intraabdominal and intrathoracic regions), and lack of mechanical fat (orbital regions, palms, soles and joints). Patients with CGL2 also have a higher prevalence of intellectual impairment and cardiomyopathy than those with CGL1.",
"   </p>",
"   <p>",
"    The patient with CAV-1 mutation reportedly has clinical features similar to those of patients with CGL1 and CGL2, with the degree of lipodystrophy being intermediate between these two phenotypes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Metabolic abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Insulin resistance has been noted at an early age. Diabetes mellitus usually develops in the early teens, but ketosis is rare, and the diabetes is usually refractory to insulin therapy. Hypertriglyceridemia with high serum concentrations of both very-low-density triglycerides and chylomicrons is common, may cause acute pancreatitis and is related to the fatty liver. Serum leptin concentrations are low, consistent with near total absence of body fat [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23352/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Acquired generalized lipodystrophy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The characteristics of acquired generalized lipodystrophy are similar to those of the congenital disorder, except that the former develops in a previously healthy child or adult over a period of days to weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23352/abstract/15\">",
"     15",
"    </a>",
"    ]. Only a few dozen cases have been reported.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A previous infection has been causally linked to this syndrome, because histologic analysis of subcutaneous tissue reveals panniculitis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23352/abstract/16\">",
"     16",
"    </a>",
"    ]. Antibodies against adipocyte-membrane antigens have been detected in a few patients [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23352/abstract/17\">",
"     17",
"    </a>",
"    ], and the syndrome may coexist with other autoimmune diseases, such as Hashimoto's thyroiditis, rheumatoid arthritis, hemolytic anemia, and chronic active hepatitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;The syndrome can, as noted above, occur in children or adults, and females predominate. In most patients the loss of fat begins in adolescence and occurs over a period of weeks, months or years. Superficial veins and musculature are prominent, and hepatomegaly is a consistent finding [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23352/abstract/18\">",
"     18",
"    </a>",
"    ]. Other findings include mild hirsutism, acanthosis nigricans, muscle hypertrophy, and cirrhosis (",
"    <a class=\"graphic graphic_figure graphicRef75295 \" href=\"UTD.htm?12/33/12821\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Adipose tissue distribution",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is generalized loss of subcutaneous adipose tissue.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Metabolic abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients have severe insulin resistance, hyperinsulinemia, hypertriglyceridemia, low serum high-density-lipoprotein (HDL) cholesterol concentrations and often a high metabolic rate. Diabetes, high serum free fatty acid concentrations, and excessive lipolysis are present. Most patients do not become ketotic, but diabetic ketoacidosis has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23352/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/57/28567?source=see_link\">",
"     \"Insulin resistance: Definition and clinical spectrum\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     PARTIAL LIPODYSTROPHY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several distinct syndromes of regional lipoatrophy, often familial in nature, are associated with a simultaneous hypertrophy of adipose tissue in nonatrophic areas.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Familial partial lipodystrophy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Familial partial lipodystrophy (FPLD) syndromes are rare syndromes characterized by variable loss of adipose tissue that occurs during childhood, puberty, or young adulthood. They are associated with metabolic complications, and in some cases, cardiomyopathy, conduction disturbances, and congestive heart failure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     FPLD type 1",
"    </span>",
"    &nbsp;&mdash;&nbsp;FPLD type 1 (Kobberling's syndrome) is characterized by loss of adipose tissue in the extremities and normal adipose tissue elsewhere. Affected individuals may have excessive amounts of subcutaneous truncal fat. Only a few affected women have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23352/abstract/20,21\">",
"     20,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The age of onset, mode of inheritance, and characteristic features are not well-defined, due to the small number of cases described. Lipodystrophy and remarkable well-defined muscles are the most frequently described clinical characteristics. Most reported patients have had hypertriglyceridemia and diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23352/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The genetic defect associated with Kobberling-type lipodystrophy is currently unknown, and no LMNA or PPARG mutations have been identified. Although it appears that this syndrome is familial, it may also occur spontaneously.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     FPLD type 2",
"    </span>",
"    &nbsp;&mdash;&nbsp;FPLD type 2 (Dunnigan's syndrome) is associated with fat loss from the extremities, abdomen, and thorax, and excess subcutaneous fat in the chin and supraclavicular area [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23352/abstract/22-25\">",
"     22-25",
"    </a>",
"    ]. The prevalence of this syndrome has been estimated to be less than 1 in 15 million [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23352/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The patients have normal adipose tissue in childhood, but lose subcutaneous adipose tissue from the extremities later, usually with the onset of puberty. The syndrome is associated with increased muscularity, not merely the appearance of increased muscularity that occurs with loss of subcutaneous fat, which makes it relatively easier to recognize in women. Muscle biopsies from individuals with the syndrome reveal hypertrophy of Type 1 and 2 muscle fibers [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23352/abstract/26\">",
"     26",
"    </a>",
"    ]. Patients may develop excess supraclavicular fat and round facies later in life. They also may have acanthosis nigricans, hirsutism, and menstrual abnormalities (ovarian hyperandrogenism) (",
"    <a class=\"graphic graphic_figure graphicRef60538 \" href=\"UTD.htm?15/21/15711\">",
"     figure 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Diabetes may develop after the age of 20 years [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23352/abstract/22\">",
"     22",
"    </a>",
"    ] and is accompanied by hypertriglyceridemia (hyperchylomicronemia), low serum HDL cholesterol concentrations, and high fasting serum free fatty acid concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23352/abstract/27,28\">",
"     27,28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although this disorder was thought to be transmitted as an X-linked dominant trait, there is autosomal dominant transmission in some families [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23352/abstract/27,29-32\">",
"     27,29-32",
"    </a>",
"    ]. The locus for the autosomal dominant form is located on chromosome 1q21-22 [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23352/abstract/30\">",
"     30",
"    </a>",
"    ]. The mutations appear to involve the LMNA gene, which encodes nuclear lamins A and C, nuclear envelope proteins that organize nuclear architecture through structural attachments that vary during the cell cycle and cell differentiation [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23352/abstract/33\">",
"     33",
"    </a>",
"    ]. A less severe phenotype has been described in two sisters whose mutation involved lamin A only [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23352/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most mutations in LMNA are missense mutations within the 3' end of the gene [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23352/abstract/35\">",
"     35",
"    </a>",
"    ]. The mutant gene products may disrupt interaction with chromatin or other nuclear lamina proteins, resulting in apoptosis and premature death of adipocytes. The accumulation of pre-laminin A may also impair adipogenesis by interfering with the key adipocyte transcription",
"    <span class=\"nowrap\">",
"     factors/regulators,",
"    </span>",
"    including sterol response element binding proteins 1 (SREBP 1) and proxisome proliferator-activated receptor gamma (PPARG).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     FPLD type 3",
"    </span>",
"    &nbsp;&mdash;&nbsp;FPLD type 3 is associated with heterozygous PPARG gene mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23352/abstract/35\">",
"     35",
"    </a>",
"    ]. Heterozygous mutations may cause loss of function by directly interfering with normal gene function (dominant negative) or by reduction of gene expression (haploinsufficiency). The phenotype is similar to Dunnigan's variety, with the exception that fat accumulation in the head and neck may be spared. Patients with FPLD3 appear to have more severe metabolic abnormalities than those with FPLD2.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Familial partial lipodystrophy has also been described in patients with mutations of AKT2 (protein kinase B), a",
"    <span class=\"nowrap\">",
"     serine/threnonine-protein",
"    </span>",
"    kinase that plays multiple roles in cell signaling, cell growth, and glycogen synthesis as well as insulin-stimulated glucose transport. Lipodystrophy in patients with AKT2 mutations is thought to be due to reduced adipocyte differentiation and dysfunctional post-receptor insulin signaling.",
"   </p>",
"   <p>",
"    A mutation in CAV1 was identified as a rare cause of partial lipodystrophy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23352/abstract/36\">",
"     36",
"    </a>",
"    ]. Two cases with different frameshift CAV1 mutations have been reported to have partial lipodystrophy with subcutaneous fat loss in the face and upper body, micrognathia, and congenital cataracts. One case was also associated with abnormal neurological findings. Diabetes, hypertriglyceridemia, and recurrent pancreatitis were reported in both cases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Mandibuloacral dysplasia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mandibuloacral dysplasia (MAD) is an extremely rare, autosomal recessive, premature aging (progeroid) syndrome, which has been reported in approximately 40 case reports [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23352/abstract/37\">",
"     37",
"    </a>",
"    ]. There are two distinctive phenotypes. Type A is considered to be due to mutations of the LMNA gene and involves the loss of subcutaneous fat from the arms and legs but normal or excessive deposition of fat in the face and neck. Type B is characterized by more generalized loss of subcutaneous fat.",
"   </p>",
"   <p>",
"    These patients carry compound heterozygous mutations in the gene encoding an endoprotease, zinc metalloprotease (ZMPSTE24), on chromosome 1q34 [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23352/abstract/38-40\">",
"     38-40",
"    </a>",
"    ]. The enzyme is important in post-translational processing of prelamin A to mature lamin A.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lipoatrophy is first noted in childhood or early adolescence, and is more marked in females [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23352/abstract/38\">",
"     38",
"    </a>",
"    ]. In addition to lipodystrophy, this disorder is characterized by postnatal growth retardation, craniofacial and skeletal abnormalities (mandibular and clavicular hypoplasia, delayed closure of the cranial sutures, acro-osteolysis, joint contractures, bird-like face, dental abnormalities), and cutaneous changes (restrictive dermatopathy, skin atrophy, alopecia and mottled cutaneous pigmentation). Dysmorphic manifestations and progeroid features become more prominent with time, and the full clinical phenotype is recognizable during the early school years. The patients have normal intelligence.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Metabolic abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperinsulinemia, insulin resistance, impaired glucose intolerance, diabetes mellitus, and hyperlipidemia have been reported in some patients, whereas serum leptin concentration can be low or normal. Focal segmental glomerulosclerosis has been reported in patients with ZMPSTE24 deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23352/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Barraquer-Simons' syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 250 patients have been reported with this syndrome (also known as partial acquired cephalothoracic lipodystrophy or acquired partial lipodystrophy). It is characterized by the loss of adipose tissue from the face and upper trunk, with sparing or increased adiposity in the rest of the body (",
"    <a class=\"graphic graphic_figure graphicRef75295 \" href=\"UTD.htm?12/33/12821\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23352/abstract/42,43\">",
"     42,43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with this syndrome have accelerated complement activation and a serum immunoglobulin G, called C3 nephritic factor [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23352/abstract/44,45\">",
"     44,45",
"    </a>",
"    ], that is thought to cause lysis of adipose tissue expressing adipsin. The heterogeneity in adipsin expression in different sites of adipose tissue may explain selective adipose tissue loss.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;This disorder begins in childhood or adolescence, usually in girls, and usually after a febrile illness. Fat loss usually occurs over a period of months or years. Autoimmune disorders such as dermatomyositis, hypothyroidism, pernicious anemia, rheumatoid arthritis, temporal arteritis or mesangiocapillary glomerulonephritis have been reported in these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23352/abstract/22,46,47\">",
"     22,46,47",
"    </a>",
"    ]. Some patients have acanthosis nigricans or clinical manifestations of ovarian hyperandrogenism.",
"   </p>",
"   <p>",
"    Despite the loss of subcutaneous fat in several areas of the body, intramuscular, intraperitoneal, and perirenal fat as well as bone marrow, orbital and mediastinal fat deposition are normal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Metabolic abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patients may have hyperinsulinemia, but not severe insulin resistance. The prevalence of diabetes (approximately 7 percent) is much lower when compared to other types of lipodystrophy (over 50 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23352/abstract/43\">",
"     43",
"    </a>",
"    ]. Several patients have had serum antinuclear and anti-double stranded DNA antibodies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Renal disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;As many as 20 percent of patients develop membranoproliferative glomerulonephritis (MPGN), occurring on average 8 to 10 years after initial diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23352/abstract/43\">",
"     43",
"    </a>",
"    ]. Presence of renal insufficiency due to MPGN is an important factor in patient prognosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Lipodystrophy associated with HIV therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with human immunodeficiency virus (HIV) infection who are treated with antiretroviral therapy, and especially HIV-1 protease inhibitors can develop lipodystrophy, and these drugs are probably the cause (",
"    <a class=\"graphic graphic_figure graphicRef75295 \" href=\"UTD.htm?12/33/12821\">",
"     figure 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/43/26298?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of HIV-associated lipodystrophy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/36/44617?source=see_link\">",
"     \"Treatment of HIV-associated lipodystrophy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Localized lipodystrophies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Localized lipodystrophies are characterized by a loss of subcutaneous fat from small areas of the body but not insulin resistance or other metabolic abnormalities. Drug-induced lipodystrophy at the site of injection was a frequent complication of insulin therapy before the availability of purified human insulin but is rare now. Other medications, such as glucocorticoids and antibiotics, can also cause localized lipoatrophy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23352/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other rare causes of localized lipoatrophy include repeated pressure against any body part and lipoatrophy occurring as part of a rare syndrome called lipodystrophia centrifugalis abdominalis infantilis. This is characterized by a centrifugal loss of adipose tissue in the abdomen with somewhat erythematous and scaly changes at the periphery, which usually occurs before the age of three years. More than 50 percent of patients recover spontaneously later in life. Finally, some patients have localized lipoatrophy, ie, lack of adipose tissue in small areas of the trunk or parts of a limb, as an isolated abnormality [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23352/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     LIPODYSTROPHIES AND INSULIN RESISTANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The results of studies of the pathogenesis of insulin resistance in the context of lipoatrophy have varied regarding the presence or absence of defects at the level of insulin receptor expression, function, and signaling [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23352/abstract/48\">",
"     48",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/57/28567?source=see_link\">",
"     \"Insulin resistance: Definition and clinical spectrum\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Transgenic mice devoid of white adipose tissue have hypermetabolism, increased appetite, hyperinsulinemia, diabetes, and hepatomegaly, ie, phenotypes remarkably similar to those of humans with generalized lipodystrophy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23352/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. These mice have decreased expression of several molecules, including peroxisome proliferator-activator receptor gamma (PPARgamma), insulin receptors, insulin receptor substrates 1 and 2, and leptin, whereas expression of tumor necrosis factor alpha is increased [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23352/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. Thus, it has been proposed that possible mediators of insulin resistance in lipodystrophy include increased tumor necrosis factor, free fatty acids, or leptin",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    adiponectin deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23352/abstract/49-51\">",
"     49-51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Transplantation of adipose tissue or leptin treatment in diabetic, insulin-resistant mice with lipodystrophy and low serum leptin concentrations results in improved glycemia and decreased serum insulin concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23352/abstract/48,52\">",
"     48,52",
"    </a>",
"    ]. In addition, replacing either adiponectin or leptin in an animal model of lipodystrophy, insulin resistance, and the metabolic syndrome improves insulin resistance, whereas replacing both adiponectin and leptin fully normalizes insulin resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23352/abstract/53\">",
"     53",
"    </a>",
"    ]. These results are consistent with the hypothesis that leptin, adiponectin,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    other substances secreted by adipose tissue are critical mediators of insulin resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23352/abstract/51\">",
"     51",
"    </a>",
"    ], but their role in humans remains to be fully elucidated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     TREATMENT OF LIPODYSTROPHY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Cosmetic treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Facial reconstruction with free flaps and silicone or other implants have been used to 'replace' adipose tissue. Conversely, liposuction or lipectomy has been used for removal of excess fat. The indications for these treatments are not defined, and their effects are variable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Diet",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no diet that reverses lipoatrophy, but in general a low-fat diet is recommended. When hypertriglyceridemia is a prominent feature, a balanced low-fat, low-carbohydrate diet that does not increase serum triglyceride concentrations is preferable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no specific drugs for lipodystrophy. A fibrate or the combination of a fibrate and a statin can be given for hypertriglyceridemia. Insulin sensitizers (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    ) may be helpful and insulin, administered in very high doses, is effective in several cases but may fail to provide adequate control of diabetes in cases with extreme insulin resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23352/abstract/54\">",
"     54",
"    </a>",
"    ]; administration of insulin-like growth factor-1 has led to improvement in glycemic control and insulin resistance in short-term studies, as it does in patients with type 2 diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23352/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients with lipodystrophy and diabetes, both",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23352/abstract/56\">",
"     56",
"    </a>",
"    ] and thiazolidinediones, such as troglitazone (which is no longer available), may reduce hyperglycemia and hyperlipidemia [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23352/abstract/57\">",
"     57",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/37/27226?source=see_link\">",
"     \"Prevalence of and risk factors for coronary heart disease in diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/38/36458?source=see_link\">",
"     \"Overview of medical care in adults with diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h3\">",
"     Leptin replacement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Leptin replacement therapy may be effective in patients with lipodystrophy who are leptin-deficient. In uncontrolled studies, recombinant leptin administered subcutaneously once or twice daily for up to 12 months to achieve physiologic serum leptin concentrations resulted in significant clinical improvements [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23352/abstract/58-64\">",
"     58-64",
"    </a>",
"    ]. Significant decreases were seen in A1C, serum triglyceride concentrations, liver volume, caloric intake, and resting metabolic rate. In a subset of these patients undergoing hyperinsulinemic-euglycemic clamp studies, leptin therapy improved peripheral glucose disposal and decreased both hepatic glucose output and hepatic steatosis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23352/abstract/59\">",
"     59",
"    </a>",
"    ]. Satiation (time to voluntary cessation of eating) and satiety (inter-meal interval) also improved with exogenous leptin therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23352/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, long-term (12 months) recombinant human leptin therapy was effective in treating insulin resistance in two subjects with type 1 diabetes and acquired lipodystrophy with insulin resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23352/abstract/65\">",
"     65",
"    </a>",
"    ]. Randomized trials of leptin in patients with various metabolic abnormalities and lipodystrophy are necessary to confirm its therapeutic role and mechanism of action.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     HIV lipodystrophy",
"    </span>",
"    &nbsp;&mdash;&nbsp;To date, there are no treatments for HIV lipodystrophy with proven benefit, although",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2472?source=see_link\">",
"     rosiglitazone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/28/43463?source=see_link\">",
"     pioglitazone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    , growth hormone, growth hormone-releasing hormone, and recombinant human leptin have been tried with variable success. Treatment of HIV lipodystrophy is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/36/44617?source=see_link\">",
"     \"Treatment of HIV-associated lipodystrophy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The lipodystrophic syndromes are a heterogeneous group of congenital or acquired disorders characterized by either complete or partial lack of adipose tissue (lipoatrophy) (",
"      <a class=\"graphic graphic_table graphicRef71384 \" href=\"UTD.htm?36/47/37627\">",
"       table 2",
"      </a>",
"      ). In some of these disorders there is also the apparent accumulation of fat in other regions of the body. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The extent of fat loss correlates with the severity of the metabolic abnormalities. Clinically, patients with severe lipodystrophy have severe insulin resistance and a group of unique features, such as severe hyperlipidemia and progressive liver disease (",
"      <a class=\"graphic graphic_table graphicRef79962 \" href=\"UTD.htm?23/0/23563\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Generalized lipodystrophy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is an increasing understanding of the molecular basis for these disorders and it is likely that multiple molecular defects are responsible. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Congenital generalized lipodystrophy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are no specific drugs for lipodystrophy. A fibrate or the combination of a fibrate and a statin can be given for hypertriglyceridemia. Insulin sensitizers may be helpful and insulin, administered in very high doses, is effective in several cases but may fail to provide adequate control of diabetes in cases with extreme insulin resistance. (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Treatment of lipodystrophy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23352/abstract/1\">",
"      Garg A. Acquired and inherited lipodystrophies. N Engl J Med 2004; 350:1220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23352/abstract/2\">",
"      Chan JL, Oral EA. Clinical classification and treatment of congenital and acquired lipodystrophy. Endocr Pract 2010; 16:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23352/abstract/3\">",
"      Javor ED, Moran SA, Young JR, et al. Proteinuric nephropathy in acquired and congenital generalized lipodystrophy: baseline characteristics and course during recombinant leptin therapy. J Clin Endocrinol Metab 2004; 89:3199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23352/abstract/4\">",
"      Musso C, Javor E, Cochran E, et al. Spectrum of renal diseases associated with extreme forms of insulin resistance. Clin J Am Soc Nephrol 2006; 1:616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23352/abstract/5\">",
"      BERARDINELLI W. An undiagnosed endocrinometabolic syndrome: report of 2 cases. J Clin Endocrinol Metab 1954; 14:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23352/abstract/6\">",
"      SEIP M. Lipodystrophy and gigantism with associated endocrine manifestations. A new diencephalic syndrome? Acta Paediatr 1959; 48:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23352/abstract/7\">",
"      LAWRENCE RD. Lipodystrophy and hepatomegaly, with diabetes, lipaemia, and other metabolic disturbances; a case throwing new light on the action of insulin. Lancet 1946; 1:724 passim.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23352/abstract/8\">",
"      Garg A, Wilson R, Barnes R, et al. A gene for congenital generalized lipodystrophy maps to human chromosome 9q34. J Clin Endocrinol Metab 1999; 84:3390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23352/abstract/9\">",
"      Magr&eacute; J, Del&eacute;pine M, Khallouf E, et al. Identification of the gene altered in Berardinelli-Seip congenital lipodystrophy on chromosome 11q13. Nat Genet 2001; 28:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23352/abstract/10\">",
"      Garg A, Agarwal AK. Lipodystrophies: disorders of adipose tissue biology. Biochim Biophys Acta 2009; 1791:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23352/abstract/11\">",
"      Kim CA, Del&eacute;pine M, Boutet E, et al. Association of a homozygous nonsense caveolin-1 mutation with Berardinelli-Seip congenital lipodystrophy. J Clin Endocrinol Metab 2008; 93:1129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23352/abstract/12\">",
"      Chandalia M, Garg A, Vuitch F, Nizzi F. Postmortem findings in congenital generalized lipodystrophy. J Clin Endocrinol Metab 1995; 80:3077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23352/abstract/13\">",
"      Agarwal AK, Simha V, Oral EA, et al. Phenotypic and genetic heterogeneity in congenital generalized lipodystrophy. J Clin Endocrinol Metab 2003; 88:4840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23352/abstract/14\">",
"      Pardini VC, Vict&oacute;ria IM, Rocha SM, et al. Leptin levels, beta-cell function, and insulin sensitivity in families with congenital and acquired generalized lipoatropic diabetes. J Clin Endocrinol Metab 1998; 83:503.",
"     </a>",
"    </li>",
"    <li>",
"     K&ouml;bberling J. Genetic syndromes associated with lipoatrophic diabetes. In: The Genetics of Diabetes Mellitus, Creutzfeldt W, K&ouml;bberling J, Neel JV (Eds), Springer-Verlag, New York 1976. p.147.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23352/abstract/16\">",
"      Billings JK, Milgraum SS, Gupta AK, et al. Lipoatrophic panniculitis: a possible autoimmune inflammatory disease of fat. Report of three cases. Arch Dermatol 1987; 123:1662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23352/abstract/17\">",
"      H&uuml;bler A, Abendroth K, Keiner T, et al. Dysregulation of insulin-like growth factors in a case of generalized acquired lipoatrophic diabetes mellitus (Lawrence Syndrome) connected with autoantibodies against adipocyte membranes. Exp Clin Endocrinol Diabetes 1998; 106:79.",
"     </a>",
"    </li>",
"    <li>",
"     Flier JS, Mantzoros C. Syndromes of extreme insulin resistance. In: Principles and Practice of Endocrinology and Metabolism, 3rd, Becker K (Ed), Lippincott Williams and Wilkins, Philadelphia 2001. p.1369.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23352/abstract/19\">",
"      Kikkawa R, Hoshi M, Shigeta Y, Izumi K. Lack of ketosis in lipoatrophic diabetes. Diabetes 1972; 21:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23352/abstract/20\">",
"      Dunnigan MG, Cochrane MA, Kelly A, Scott JW. Familial lipoatrophic diabetes with dominant transmission. A new syndrome. Q J Med 1974; 43:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23352/abstract/21\">",
"      Herbst KL, Tannock LR, Deeb SS, et al. K&ouml;bberling type of familial partial lipodystrophy: an underrecognized syndrome. Diabetes Care 2003; 26:1819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23352/abstract/22\">",
"      Garg A. Lipodystrophies. Am J Med 2000; 108:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23352/abstract/23\">",
"      K&ouml;bberling J, Willms B, Kattermann R, Creutzfeldt W. Lipodystrophy of the extremities. A dominantly inherited syndrome associated with lipatrophic diabetes. Humangenetik 1975; 29:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23352/abstract/24\">",
"      Speckman RA, Garg A, Du F, et al. Mutational and haplotype analyses of families with familial partial lipodystrophy (Dunnigan variety) reveal recurrent missense mutations in the globular C-terminal domain of lamin A/C. Am J Hum Genet 2000; 66:1192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23352/abstract/25\">",
"      Garg A, Peshock RM, Fleckenstein JL. Adipose tissue distribution pattern in patients with familial partial lipodystrophy (Dunnigan variety). J Clin Endocrinol Metab 1999; 84:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23352/abstract/26\">",
"      Spuler S, Kalbhenn T, Zabojszcza J, et al. Muscle and nerve pathology in Dunnigan familial partial lipodystrophy. Neurology 2007; 68:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23352/abstract/27\">",
"      Jackson SN, Howlett TA, McNally PG, et al. Dunnigan-Kobberling syndrome: an autosomal dominant form of partial lipodystrophy. QJM 1997; 90:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23352/abstract/28\">",
"      Ursich MJ, Fukui RT, Galv&atilde;o MS, et al. Insulin resistance in limb and trunk partial lipodystrophy (type 2 K&ouml;bberling-Dunnigan syndrome). Metabolism 1997; 46:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23352/abstract/29\">",
"      Garg A. Gender differences in the prevalence of metabolic complications in familial partial lipodystrophy (Dunnigan variety). J Clin Endocrinol Metab 2000; 85:1776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23352/abstract/30\">",
"      Peters JM, Barnes R, Bennett L, et al. Localization of the gene for familial partial lipodystrophy (Dunnigan variety) to chromosome 1q21-22. Nat Genet 1998; 18:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23352/abstract/31\">",
"      Anderson JL, Khan M, David WS, et al. Confirmation of linkage of hereditary partial lipodystrophy to chromosome 1q21-22. Am J Med Genet 1999; 82:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23352/abstract/32\">",
"      Vantyghem MC, Pigny P, Maurage CA, et al. Patients with familial partial lipodystrophy of the Dunnigan type due to a LMNA R482W mutation show muscular and cardiac abnormalities. J Clin Endocrinol Metab 2004; 89:5337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23352/abstract/33\">",
"      Cao H, Hegele RA. Nuclear lamin A/C R482Q mutation in canadian kindreds with Dunnigan-type familial partial lipodystrophy. Hum Mol Genet 2000; 9:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23352/abstract/34\">",
"      Garg A, Vinaitheerthan M, Weatherall PT, Bowcock AM. Phenotypic heterogeneity in patients with familial partial lipodystrophy (dunnigan variety) related to the site of missense mutations in lamin a/c gene. J Clin Endocrinol Metab 2001; 86:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23352/abstract/35\">",
"      Agarwal AK, Garg A. A novel heterozygous mutation in peroxisome proliferator-activated receptor-gamma gene in a patient with familial partial lipodystrophy. J Clin Endocrinol Metab 2002; 87:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23352/abstract/36\">",
"      Cao H, Alston L, Ruschman J, Hegele RA. Heterozygous CAV1 frameshift mutations (MIM 601047) in patients with atypical partial lipodystrophy and hypertriglyceridemia. Lipids Health Dis 2008; 7:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23352/abstract/37\">",
"      Simha V, Agarwal AK, Oral EA, et al. Genetic and phenotypic heterogeneity in patients with mandibuloacral dysplasia-associated lipodystrophy. J Clin Endocrinol Metab 2003; 88:2821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23352/abstract/38\">",
"      Jackson SN, Pinkney J, Bargiotta A, et al. A defect in the regional deposition of adipose tissue (partial lipodystrophy) is encoded by a gene at chromosome 1q. Am J Hum Genet 1998; 63:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23352/abstract/39\">",
"      Novelli G, Muchir A, Sangiuolo F, et al. Mandibuloacral dysplasia is caused by a mutation in LMNA-encoding lamin A/C. Am J Hum Genet 2002; 71:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23352/abstract/40\">",
"      Agarwal AK, Kazachkova I, Ten S, Garg A. Severe mandibuloacral dysplasia-associated lipodystrophy and progeria in a young girl with a novel homozygous Arg527Cys LMNA mutation. J Clin Endocrinol Metab 2008; 93:4617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23352/abstract/41\">",
"      Agarwal AK, Zhou XJ, Hall RK, et al. Focal segmental glomerulosclerosis in patients with mandibuloacral dysplasia owing to ZMPSTE24 deficiency. J Investig Med 2006; 54:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23352/abstract/42\">",
"      Barraquer, FL. Pathogenesis of progressive cephalothoracic lipodystrophy. J Nerv Ment Dis 1949; 109:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23352/abstract/43\">",
"      Misra A, Peethambaram A, Garg A. Clinical features and metabolic and autoimmune derangements in acquired partial lipodystrophy: report of 35 cases and review of the literature. Medicine (Baltimore) 2004; 83:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23352/abstract/44\">",
"      Mathieson PW, Peters K. Are nephritic factors nephritogenic? Am J Kidney Dis 1994; 24:964.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23352/abstract/45\">",
"      Mathieson PW, W&uuml;rzner R, Oliveria DB, et al. Complement-mediated adipocyte lysis by nephritic factor sera. J Exp Med 1993; 177:1827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23352/abstract/46\">",
"      Peters DK, Charlesworth JA, Sissons JG, et al. Mesangiocapillary nephritis, partial lipodystrophy, and hypocomplementaemia. Lancet 1973; 2:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23352/abstract/47\">",
"      Sissons JG, West RJ, Fallows J, et al. The complement abnormalities of lipodystrophy. N Engl J Med 1976; 294:461.",
"     </a>",
"    </li>",
"    <li>",
"     Flier JS, Mantzoros C. Syndromes of severe insulin resistance and mutant insulin. In: Endocrinology, 4th, De Groot L, Jameson JL (Eds), WB Saunders, Philadelphia 2001. p.799.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23352/abstract/49\">",
"      Shimomura I, Hammer RE, Richardson JA, et al. Insulin resistance and diabetes mellitus in transgenic mice expressing nuclear SREBP-1c in adipose tissue: model for congenital generalized lipodystrophy. Genes Dev 1998; 12:3182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23352/abstract/50\">",
"      Moitra J, Mason MM, Olive M, et al. Life without white fat: a transgenic mouse. Genes Dev 1998; 12:3168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23352/abstract/51\">",
"      Ahima RS, Flier JS. Adipose tissue as an endocrine organ. Trends Endocrinol Metab 2000; 11:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23352/abstract/52\">",
"      Ogawa Y, Masuzaki H, Hosoda K, et al. Increased glucose metabolism and insulin sensitivity in transgenic skinny mice overexpressing leptin. Diabetes 1999; 48:1822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23352/abstract/53\">",
"      Yamauchi T, Kamon J, Waki H, et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001; 7:941.",
"     </a>",
"    </li>",
"    <li>",
"     Mantzoros CS, Moses AC. Treatment of severe insulin resistance. In: Androgen excess disorders in women, Azziz R, Nestler JE, Dewailly D (Eds), Lippincott Raven, Philadelphia 1997. p.247.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23352/abstract/55\">",
"      Kuzuya H, Matsuura N, Sakamoto M, et al. Trial of insulinlike growth factor I therapy for patients with extreme insulin resistance syndromes. Diabetes 1993; 42:696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23352/abstract/56\">",
"      Vantyghem MC, Vigouroux C, Magr&eacute; J, et al. Late-onset lipoatrophic diabetes. Phenotypic and genotypic familial studies and effect of treatment with metformin and lispro insulin analog. Diabetes Care 1999; 22:1374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23352/abstract/57\">",
"      Arioglu E, Duncan-Morin J, Sebring N, et al. Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes. Ann Intern Med 2000; 133:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23352/abstract/58\">",
"      Oral EA, Simha V, Ruiz E, et al. Leptin-replacement therapy for lipodystrophy. N Engl J Med 2002; 346:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23352/abstract/59\">",
"      Petersen KF, Oral EA, Dufour S, et al. Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy. J Clin Invest 2002; 109:1345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23352/abstract/60\">",
"      McDuffie JR, Riggs PA, Calis KA, et al. Effects of exogenous leptin on satiety and satiation in patients with lipodystrophy and leptin insufficiency. J Clin Endocrinol Metab 2004; 89:4258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23352/abstract/61\">",
"      Javor ED, Cochran EK, Musso C, et al. Long-term efficacy of leptin replacement in patients with generalized lipodystrophy. Diabetes 2005; 54:1994.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23352/abstract/62\">",
"      Oral EA, Chan JL. Rationale for leptin-replacement therapy for severe lipodystrophy. Endocr Pract 2010; 16:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23352/abstract/63\">",
"      Chong AY, Lupsa BC, Cochran EK, Gorden P. Efficacy of leptin therapy in the different forms of human lipodystrophy. Diabetologia 2010; 53:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23352/abstract/64\">",
"      Mantzoros CS. W(h)ither metreleptin for lipodystrophy and the metabolic syndrome? Endocr Pract 2010; 16:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23352/abstract/65\">",
"      Park JY, Chong AY, Cochran EK, et al. Type 1 diabetes associated with acquired generalized lipodystrophy and insulin resistance: the effect of long-term leptin therapy. J Clin Endocrinol Metab 2008; 93:26.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1788 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-122.72.76.133-CAE5397922-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_51_23352=[""].join("\n");
var outline_f22_51_23352=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H34\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENERALIZED LIPODYSTROPHY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Congenital generalized lipodystrophy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Clinical features",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Metabolic abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Acquired generalized lipodystrophy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Clinical features",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Adipose tissue distribution",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Metabolic abnormalities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      PARTIAL LIPODYSTROPHY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Familial partial lipodystrophy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - FPLD type 1",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - FPLD type 2",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - FPLD type 3",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Other",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Mandibuloacral dysplasia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Clinical features",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Metabolic abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Barraquer-Simons' syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Clinical features",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Metabolic abnormalities",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Renal disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Lipodystrophy associated with HIV therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Localized lipodystrophies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      LIPODYSTROPHIES AND INSULIN RESISTANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      TREATMENT OF LIPODYSTROPHY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Cosmetic treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Diet",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Drugs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      - Leptin replacement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      HIV lipodystrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/1788\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/1788|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?42/51/43825\" title=\"figure 1\">",
"      Congenital gen lipodystrophy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/33/12821\" title=\"figure 2\">",
"      Acquired lipodystrophy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?15/21/15711\" title=\"figure 3\">",
"      FPLD type 2",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/1788|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/0/23563\" title=\"table 1\">",
"      Manifestations of lipodystrophy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/47/37627\" title=\"table 2\">",
"      Classification lipodystrophy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/41/3739\" title=\"table 3\">",
"      Differential dx of lipodystro",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/43/26298?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of HIV-associated lipodystrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/57/28567?source=related_link\">",
"      Insulin resistance: Definition and clinical spectrum",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/38/36458?source=related_link\">",
"      Overview of medical care in adults with diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/37/27226?source=related_link\">",
"      Prevalence of and risk factors for coronary heart disease in diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/36/44617?source=related_link\">",
"      Treatment of HIV-associated lipodystrophy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_51_23353="Extragenital lichen sclerosus in dark skin";
var content_f22_51_23353=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F51592%7EDERM%2F59300&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F51592%7EDERM%2F59300&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Extragenital lichen sclerosus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Atrophic plaques with mottled hyperpigmentation are present on the shoulder and arm.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Extragenital lichen sclerosus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple hyperpigmented and hypopigmented papules are present on the ventral wrists.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_51_23353=[""].join("\n");
var outline_f22_51_23353=null;
var title_f22_51_23354="Specific viruses that cause arthritis";
var content_f22_51_23354=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Specific viruses that cause arthritis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/51/23354/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/51/23354/contributors\">",
"     Terry L Moore, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/51/23354/contributors\">",
"     Reema Syed, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/51/23354/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/51/23354/contributors\">",
"     Peter H Schur, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/51/23354/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/51/23354/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/51/23354/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 14, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Arthralgia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    arthritis are well-recognized and relatively common occurrences with viral infections. This topic will review the more common viral infections that can cause arthritic symptoms. An overview of pathogenesis and diagnosis of viral arthritis is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/33/1558?source=see_link\">",
"     \"Pathogenesis and diagnosis of viral arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     HEPATITIS A VIRUS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In hepatitis A virus (HAV) infections, arthralgias and rash occur in 10 to 14 percent of patients, but arthritis is extremely rare and there is some suspicion that patients with arthritis attributed to HAV infection truly had hepatitis C (HCV). Arthritis occurred primarily in patients with vasculitis who had a chronic relapsing form of hepatitis A, and also high titer of polyclonal IgG and IgM circulating cryoglobulins (type III cryoglobulinemia) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23354/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     HEPATITIS B VIRUS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Individuals infected with the hepatitis B virus (HBV) can be either asymptomatic or symptomatic. Asymptomatic infection is more common than the latter, especially in young children. Most primary infections in adults are self-limited, with clearance of the virus from the blood and liver and the development of lasting immunity to reinfection [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23354/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. However, some primary infections in healthy adults, generally less than 5 percent, do not resolve, but develop into persistent infections. This is manifested by serological evidence of a primary infection by the appearance of hepatitis B surface antigen (HBsAg), followed shortly by IgM antibodies against HBV core antigen (anti-HBc antibodies), then circulating HBeAg becomes detectable.",
"   </p>",
"   <p>",
"    Clinically, a prodromal phase of one to six months is followed by the onset of nonspecific symptoms including fever, nausea, vomiting, anorexia, and abdominal pain which generally precedes the onset of icterus by 1 to 14 days [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23354/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. In such cases, viral replication continues in the liver and there is continued viremia, although the titers of the virus in the liver and blood are variable.",
"   </p>",
"   <p>",
"    People with subclinical persistent infection, normal serum aminotransferase levels, and nearly normal findings on liver biopsy are termed asymptomatic chronic HBV carriers; those with abnormal liver function and histologic features are classified as having chronic hepatitis B. During the prodromal phase and the early phase of clinical disease, HBsAg may be evident in the circulation. Only later does anti-HBsAg appear with a subsequent clearance of circulating viral products. Joint symptoms associated with HBV infections are believed to be due to the formation and deposition of immune complexes; cryoprecipitates containing HBs Ag and complement components have been reported in affected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23354/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Affected patients may have an earlier anti-HBs antigen response, promoting immune complex formation [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23354/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ten to 25 percent of patients with HBV develop joint symptoms and arthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23354/abstract/6\">",
"     6",
"    </a>",
"    ]. It can be symmetrical, migratory or additive, and arthritis usually occurs in the prodromal stage of the disease at a time when there may be no other clinical manifestations of hepatitis. Women have a higher incidence than men. The joints of the hands and knees are most often affected, but wrists, ankles, elbows, shoulders, and other large joints can also be affected and morning stiffness is common [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23354/abstract/2,6,7\">",
"     2,6,7",
"    </a>",
"    ]. Joint symptoms tend to persist for days to weeks, and commonly resolve with the onset of jaundice [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23354/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Skin involvement is a common accompaniment of HBV-associated arthritis and often appears coincidence with the joint symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23354/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Urticarial and maculopapular eruptions primarily involving the lower extremities are most typical.",
"   </p>",
"   <p>",
"    The patients with acute hepatitis B associated arthritis may have abnormal liver function tests with transient decreases in complement levels, and increasing levels of circulating immune complexes. The diagnosis of HBV infection must be confirmed by serological evidence of viral infection [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23354/abstract/2,6,7\">",
"     2,6,7",
"    </a>",
"    ]. In individuals with chronic HBV infection, arthritis may persist for longer periods of time and other laboratory and clinical manifestations of immune complex mediated disease may be present. These include evidence of clinical syndromes such as polyarteritis nodosa [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23354/abstract/8\">",
"     8",
"    </a>",
"    ], glomerulonephritis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23354/abstract/9\">",
"     9",
"    </a>",
"    ], and essential mixed cryoglobulinemia [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23354/abstract/10\">",
"     10",
"    </a>",
"    ]. Examination of joint fluid may reveal inflammatory changes [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23354/abstract/2\">",
"     2",
"    </a>",
"    ]. Management is limited to symptomatic supportive care. The joint disease is always self-limited with no reports of progression to chronic arthritis or evidence of joint damage [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23354/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     HEPATITIS C VIRUS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatitis C virus (HCV) is a common cause of persistent viral infection. It is often discovered in an asymptomatic individual because of elevated transaminase levels noted on comprehensive metabolic panel. Many infected patients have extrahepatic symptoms including arthralgias and myalgias [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23354/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. A significant number of patients with HCV infection demonstrate an antibody response to viral products that result in the formation of circulating immune complexes. These immune complexes may then deposit in tissues producing the clinical manifestation of mixed essential cryoglobulinemia that includes arthritis, glomerulonephritis, and vasculitis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23354/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. Essential mixed cryoglobulinemia is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/15/34040?source=see_link\">",
"     \"Clinical manifestations and diagnosis of the mixed cryoglobulinemia syndrome (essential mixed cryoglobulinemia)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Arthritis is noted in 2 to 20 percent of HCV patients [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23354/abstract/12,14\">",
"     12,14",
"    </a>",
"    ]. The arthritis is an evanescent rheumatoid-like picture in two-thirds of the cases and an oligoarthritis in the rest. Nonsteroidal anti-inflammatory drugs (NSAIDs) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"     hydroxychloroquine",
"    </a>",
"    may be helpful, but conventional treatment of arthritis may be problematic in the context of viral hepatitic arthropathy. The emergence of more effective antiviral treatments and the combination with biologics may provide more effective treatment for the inflammatory arthritis associated with chronic HCV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23354/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/52/36682?source=see_link\">",
"     \"Treatment of the mixed cryoglobulinemia syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PARVOVIRUS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Parvovirus B19 is the only known parvovirus that infects humans. It is the cause of fifth disease or erythema infectiosum, a self-limited febrile-rash producing disease of childhood. Infections can also cause arthralgias or arthritis. A B19 infection can also present as a nonspecific febrile illness with a connective tissue disease like syndrome, both in children and adults [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23354/abstract/15,16\">",
"     15,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This syndrome is manifested by rash,",
"    <span class=\"nowrap\">",
"     arthralgias/arthritis,",
"    </span>",
"    laboratory abnormalities, and other connective tissue disease like symptoms. Parvoviral infections sometimes mimic systemic lupus (SLE) in adults and children [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23354/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]; a role for B19 infection in the pathogenesis of SLE has been proposed by some authors, but remains unproven [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23354/abstract/17\">",
"     17",
"    </a>",
"    ]. B19 infections can also cause severe catastrophic illness with life threatening aplastic anemia [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23354/abstract/18\">",
"     18",
"    </a>",
"    ]. Non-articular manifestations of parvoviral infection are discussed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/54/22377?source=see_link\">",
"     \"Clinical manifestations and pathogenesis of human parvovirus B19 infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Joint symptoms occur in about 8 percent of infected children and 60 percent of infected adults. Arthralgias or arthritis may accompany or follow the skin eruption. Arthropathy occurs more commonly in women (59 percent) than in men (30 percent) with many adults having arthritis alone without other preceding or concurrent symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23354/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. A typical pattern in adults is acute onset symmetrical polyarticular arthritis with the proximal interphalangeal and metacarpophalangeal joints most commonly affected. In children, the arthropathy can be asymmetric and pauciarticular, affecting the knees most often [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23354/abstract/20\">",
"     20",
"    </a>",
"    ]. Arthralgias are more frequent than actual joint swelling, although both may occur. Joint stiffness is common. The joint symptoms may persist for weeks to occasionally months with resolution, but recurrences are reported [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23354/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    At times the children may meet criteria for juvenile idiopathic arthritis. A child's anti-B19 antibodies may cross-react with other antigens, leading to autoantibody formation and immune complex deposition [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23354/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Parvovirus B19 does not appear to be a specific cause of rheumatoid arthritis. Patients with rheumatoid arthritis are not more likely to be seropositive for parvovirus than are controls [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23354/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. Conversely, B19 arthropathy does not progress to rheumatoid arthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23354/abstract/24\">",
"     24",
"    </a>",
"    ]. Parvovirus B19 DNA may be present in inflamed joints, but is also found in equivalent proportion of control samples of synovial tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23354/abstract/25\">",
"     25",
"    </a>",
"    ]. However, in an animal model, the transfer of a parvovirus B19 genetic element encoding a nonstructural protein conferred susceptibility to collagen induced arthritis in an otherwise arthritis-resistant strain [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23354/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The diagnosis of acute parvovirus infection is made by finding circulating IgM antibody to parvovirus [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23354/abstract/18,20\">",
"     18,20",
"    </a>",
"    ]. IgG antibody is evidence of a preexisting infection and may be found in a substantial proportion of the normal population [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23354/abstract/18,20\">",
"     18,20",
"    </a>",
"    ]. Laboratory findings are, otherwise, remarkably normal in most patients. The erythrocyte sedimentation rate and C-reactive protein are occasionally elevated. The leukocyte count remains normal, but rheumatoid factor and antinuclear antibody may be present in the acute period in some cases, but may be transient in nature [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23354/abstract/20\">",
"     20",
"    </a>",
"    ]. Therapy for acute parvoviral infections with",
"    <span class=\"nowrap\">",
"     arthralgias/arthritis",
"    </span>",
"    is mainly supportive with NSAIDs such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/43/43705?source=see_link\">",
"     naproxen",
"    </a>",
"    in doses of 10 to 20",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    in children and 500 mg twice a day in adults usually effective for symptomatic relief.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     RUBELLA AND RUBELLA VACCINE VIRUS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rubella virus infection classically presents with acute maculopapular rash accompanied by significant lymphadenopathy involving the posterior auricular, posterior cervical, and suboccipital lymph nodes [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23354/abstract/27\">",
"     27",
"    </a>",
"    ]. The rash is light pink, beginning as a maculopapular eruption on the face and spreading to involve the trunk, hands, and feet, while sparing the palms and soles. Rubella vaccine virus and an attenuated strain of viral-type rubella virus rarely give rise to rash, fever, or lymphadenopathy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/14/26855?source=see_link\">",
"     \"Rubella\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Both rubella and rubella vaccine virus are believed to grow preferentially in synovial tissues, giving rise to symptoms because of direct infection. Both rubella and rubella vaccine virus have been cultured from joint tissues [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23354/abstract/28-31\">",
"     28-31",
"    </a>",
"    ]. Rubella virus has been shown to persist in lymphocytes recovered from people infected years earlier, thereby providing a mechanism for subsequent viral infection of the joint tissues or for production of viral products that could give rise to an immune complex mediated pathogenesis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23354/abstract/28,32,33\">",
"     28,32,33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Rubella and rubella vaccine virus are associated with a high incidence of associated arthritis; in one report, as high as 30 percent of females and 6 percent of males with rubella infection [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23354/abstract/34\">",
"     34",
"    </a>",
"    ]. The onset of joint symptoms due to rubella virus is typically abrupt, occurring in most patients within one week period before and after the rash [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23354/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. Joint symptoms usually develop approximately two weeks after vaccination with rubella virus vaccine [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23354/abstract/35\">",
"     35",
"    </a>",
"    ]. A recent study also showed that arthropathy following rubella vaccination may be higher in women who have very low pre-vaccine levels of antibody, particular in assays majoring functional (neutralizing) antibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23354/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pattern of joint involvement with both viruses is similar to that in rheumatic fever being symmetrical, migratory, and additive, with resolution of most joint symptoms within two weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23354/abstract/35,37,38\">",
"     35,37,38",
"    </a>",
"    ]. The small joints of the hands, the wrists, and the knees are most commonly involved, with the larger joints less often affected. Arthralgias are much more common than true joint swelling; however, there is often considerable pain and swelling in the soft tissues surrounding the joint as well as synovial tendon sheath involvement, occasionally leading to tenosynovitis and the carpal tunnel syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23354/abstract/35,37,38\">",
"     35,37,38",
"    </a>",
"    ]. Joint symptoms may on rare occasions persist for long periods of time, as long as a year. There, however, is no evidence of chronic joint disease or joint damage [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23354/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. Recurrence of joint symptoms, although uncommon, is seen more frequently after rubella vaccine virus inoculation, occurring in approximately 1.3 percent of the patients with joint symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23354/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The diagnosis of rubella associated arthropathy must be substantiated by either viral isolation from the nasopharynx or joint tissues, or serological evidence of an acute viral infection with an IgM response. Joint fluid findings are consistent with an inflammatory arthropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23354/abstract/30,40\">",
"     30,40",
"    </a>",
"    ]. Management is entirely symptomatic and supportive.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     ALPHAVIRUSES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alphaviruses that cause",
"    <span class=\"nowrap\">",
"     arthritis/arthralgias",
"    </span>",
"    are globally distributed mosquito-borne RNA viruses causing epidemics of",
"    <span class=\"nowrap\">",
"     polyarthritis/arthralgia,",
"    </span>",
"    with disease emerging or reemerging and increasingly being reported in travelers [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23354/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. They are maintained in nature by continuous cycles of transmission between hematophagous arthropods (usually mosquitoes) and enzootic vertebrate hosts (usually mammals or birds). Bites by infected mosquitoes can result in epizootic infections of humans, with most cases occurring after seasonal rains when mosquito numbers are high [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23354/abstract/41,42\">",
"     41,42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Diseases caused by the African and Asian arthritogenic alphaviruses have not been extensively studied because they largely occur in underdeveloped and developing countries, where they often do not represent a major health priority; however, Ross River virus disease, which affects as many as 8000 Australians annually, has received considerable attention. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/8/41095?source=see_link\">",
"     \"Ross River virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among all of the viruses that can cause arthritis, the alphaviruses are unusual, because nearly all symptomatic infections in adults result in joint symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23354/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. There are six genus of alphaviruses in the family Togaviridae, representing a group of enveloped, positive-sense single-stranded RNA arboviruses, include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ross River virus and Barmah Forest virus, which is also found in Australia and causes about 500 to 1500 symptomatic infections per year.",
"     </li>",
"     <li>",
"      The second group is Igbo-Ora, a virus related to O'nyong-nyong and found mainly in Africa, with an outbreak in 1988 [",
"      <a class=\"abstract\" href=\"UTD.htm?22/51/23354/abstract/42\">",
"       42",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The third group consists of the Sindbis virus group, which is found in Africa, Asia, and Australia, and the Sindbis-like viruses, which occur more frequently in Europe. It goes by different names of Karelian fever in Russia, Ockelbo in Sweden, and Pogosta in Finland.",
"     </li>",
"     <li>",
"      The fourth group is Mayaro, which is found mainly in South America, and has small sporadic epidemics.",
"     </li>",
"     <li>",
"      The fifth group is O'nyong-nyong, which is found in Central and East Africa with occasionally small epidemics, however, greater than two million people were involved in an epidemic from 1959 to 1962.",
"     </li>",
"     <li>",
"      The last group is Chikungunya, found mainly in South and East Asia, Africa, and the Western Pacific, with recurrent epidemics with as many as 40,000 involved Thailand in 1962 [",
"      <a class=\"abstract\" href=\"UTD.htm?22/51/23354/abstract/41-43\">",
"       41-43",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/13/15576?source=see_link\">",
"       \"Chikungunya fever\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The mechanism by which these viruses give rise to joint symptoms is mainly caused by virus persisting in synovial macrophages, with the host's inflammatory antiviral immune response giving rise to the arthritic symptoms. Virus has been detected in the joint effusions of Ross River virus patients, and Ross River virus can establish in vitro persistent productive infection in macrophages [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23354/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. These macrophage cultures also secrete inflammatory mediators associated with macrophage recruitment and activation, specifically chemokines, IL-8, and the antiviral cytokine interferon [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23354/abstract/45-47\">",
"     45-47",
"    </a>",
"    ]. Similar findings have been found in Barmah Forest virus, Chikungunya, Semliki Forest, and Sindbis viruses. T-cell derived interferon gamma is also involved in Ross River virus disease and other alphaviruses. Interferon gamma has been detected in the synovial exudate from Ross River virus patients and interferon gamma-secreting Ross River virus specific T-cells from humans and mice have been isolated [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23354/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The incubation period lasts from several days to three weeks; infection is typically associated with triad of fever, arthritis, and rash [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23354/abstract/41\">",
"     41",
"    </a>",
"    ]; however, all aspects of the triad may not be present making the diagnosis difficult at times. The symptomatic to asymptomatic ratio varies from 4:1 to 1:1 between O'nyong-nyong, Mayaro, and Ross River virus.",
"   </p>",
"   <p>",
"    In children, the disease is often clinically indistinguishable from other febrile illnesses and is usually mild with Ross River virus. The onset in Chikungunya and O'nyong-nyong viruses is abrupt with fever and joint symptoms and can be severe in nature [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23354/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. The other alphaviruses are associated with a more gradual onset of fever and nonspecific constitutional symptoms prior to joint involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23354/abstract/41\">",
"     41",
"    </a>",
"    ]. Most patients have polyarthralgias usually involving the feet, ankles, knees, lower back, fingers, wrists, elbows, shoulders,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    neck. Approximately one-third to one-half often experience rash, fever, myalgias,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    fatigue, with tendinitis and periarticular involvement also being present at times. In most cases, symptoms progressively resolve over an average of three- to six-month period, although the Ross River virus appeared to last longer than one year in an occasional patient [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23354/abstract/51,52\">",
"     51,52",
"    </a>",
"    ] and 12 percent of those with Chikungunya had chronic arthralgia lasting more than three years [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23354/abstract/53\">",
"     53",
"    </a>",
"    ]. The rash occurs several days after the onset of joint symptoms and is short-lived, involving the face, trunk, and flexor surface of the extremities. Mild lymphadenopathy may be seen with all of the viral types.",
"   </p>",
"   <p>",
"    Chikungunya has become a much more global disease with increasing world travel and global warming, with increasing arthritic symptoms including large outbreaks in Italy, India, and Indian Ocean islands [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23354/abstract/54,55\">",
"     54,55",
"    </a>",
"    ]. A 2005 to 2006 outbreak in Reunion Island showed younger patients recovered, but a chronic group developed, mainly in patients over 60 years of age. These patients had a much higher viral load. A rapid innate immune response was demonstrated by an increase in",
"    <span class=\"nowrap\">",
"     dendritic/NK/CD4/CD8",
"    </span>",
"    cell activation and accompanied by a weak",
"    <span class=\"nowrap\">",
"     Th1/Th2",
"    </span>",
"    cytokine response. Interestingly, high levels of interferon-alpha (IFN-&alpha;) mRNA was noted in lymphocytes, and circulating IL-12 levels persisted for months in the chronic group. These observed cellular and molecular events may contribute to the chronic",
"    <span class=\"nowrap\">",
"     arthralgia/arthritis",
"    </span>",
"    symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23354/abstract/43\">",
"     43",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/13/15576?source=see_link\">",
"     \"Chikungunya fever\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnosis for these diseases varies. In Australia, commercial serodiagnostic tests based on enzyme linked immunoassay (ELISA) for Barmah Forest and Ross River virus infections are available. The laboratory based tests for chikungunya, Mayaro, and Sindbis virus infections are available in several countries and usually are based on ELISA, hemagglutination inhibition, or indirect immunofluorescent assays [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23354/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    IgG seropositive results should be interpreted with caution, especially for individuals who live or have lived in endemic areas and who may be IgG seropositive because of previous infections. Serology testing performed at least two weeks apart, showing a change from IgM positive, IgG negative to IgM positive, IgG positive, IgM negative, IgG negative to IgM",
"    <span class=\"nowrap\">",
"     positive/IgG",
"    </span>",
"    positive, or IgM",
"    <span class=\"nowrap\">",
"     positive/IgG",
"    </span>",
"    negative to IgM negative, IgG positive, represents the gold standard for ELISA-based diagnosis and indicates recent infection. Alternatively, an increased titer of greater than fourfold in paired serology samples is required to indicate a recent infection using laboratory-based ELISA, hemagglutination inhibition, or indirect immunofluorescent assays [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23354/abstract/56\">",
"     56",
"    </a>",
"    ]. There may be mild leukopenia with a relative lymphocytosis present and occasional thrombocytopenia has been reported with chikungunya and Mayaro infection.",
"   </p>",
"   <p>",
"    Overall, treatment for alphavirus infection-associated arthritis is nonspecific. Nonsteroidal anti-inflammatory drugs are the best treatment for Ross River virus disease, with a simple analgesic often effective for less severe disease; glucocorticoids are not usually indicated due to the potential side effects [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23354/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     Aspirin",
"    </a>",
"    should be avoided if there is any chance of dengue fever because of risk of exacerbating hemorrhagic manifestations. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/34/18985?source=see_link\">",
"     \"Clinical presentation and diagnosis of dengue virus infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     DENGUE VIRUS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The classic findings of dengue virus (DV) infection are an acute febrile illness with headaches and marked muscle and joint pain. The term used to describe it is \"break-bone fever\" [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23354/abstract/57\">",
"     57",
"    </a>",
"    ]. Arthralgias occur in 60 to 80 percent of patients. Leukopenia, thrombocytopenia, and liver enzymes may be elevated [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23354/abstract/58\">",
"     58",
"    </a>",
"    ]. Most cases are mild, but a small percentage of patients have potentially lethal forms called dengue hemorrhagic fever and dengue shock syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23354/abstract/59\">",
"     59",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/34/18985?source=see_link\">",
"     \"Clinical presentation and diagnosis of dengue virus infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     MUMPS VIRUS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mumps virus has an incubation period of two to three weeks, usually followed by a short prodromal phase with nonspecific constitutional symptoms. Arthritis is uncommon with fewer than 100 cases reported in the literature. Parotid signs and symptoms followed with bilateral involvement in 75 percent of symptomatic patients; however, mumps virus infection is subclinical in 20 to 40 percent of cases, and some symptomatic patients do not have parotitis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23354/abstract/60,61\">",
"     60,61",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/61/8154?source=see_link\">",
"     \"Epidemiology, clinical manifestations, diagnosis and management of mumps\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Joint symptoms typically occur after the onset of parotitis. A migratory polyarthritis involving both large and small joints is the most common presentation, but disease limited to polyarthralgias or a monoarthritis can also occur [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23354/abstract/60,61\">",
"     60,61",
"    </a>",
"    ]. Low-grade fever typically accompanies the joint symptoms, which generally resolve over a period of weeks. No long-term joint damage has been reported. The mechanism by which mumps virus gives rise to joint symptoms is not known.",
"   </p>",
"   <p>",
"    Diagnosis of mumps virus is confirmed by serologic testing. Laboratory studies may show a moderate leukocytosis, and an elevated erythrocyte sedimentation rate, but patients are usually rheumatoid factor negative [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23354/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     ENTEROVIRUS INFECTIONS: COXSACKIE VIRUS AND ECHOVIRUS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Enteroviruses are endemic throughout the world. The peak incidence of disease is in the summer and fall in temperate climates. Prevalence is inversely correlated with socioeconomic status [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23354/abstract/62\">",
"     62",
"    </a>",
"    ]. The mechanism by which enteroviruses cause arthritis is not known. Virus has occasionally been isolated from involved joints, but immune complexes have not been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23354/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Isolated outbreaks of disease to specific enterovirus immunotypes are not uncommon, and have provided the best means of identifying clinical manifestations. The incubation period for viral infection is short, three to five days, and is followed by the abrupt onset of fever, headache, and other nonspecific constitutional signs and symptoms. There may be an associated maculopapular rash, pharyngitis, conjunctivitis, myalgias, nausea, vomiting, diarrhea, and abdominal pain. Symptoms are generally short-lived (two to four days), although they may recur [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23354/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Arthritis is an uncommon manifestation of enterovirus infections affecting about 0.1 percent of patients; however, with a large number of patient with this illnesses it can represent a substantial number of cases of nonspecific self-limited arthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23354/abstract/63-65\">",
"     63-65",
"    </a>",
"    ]. Joint symptoms commonly accompany some episodes of illnesses associated with fever, myalgias, evanescent rash, and constitutional symptoms. Both large and small joints may be involved. The arthritis is commonly associated with other signs of viral infection, including fever, sore throat, pleuritic pain, myocarditis, and rash.",
"   </p>",
"   <p>",
"    The diagnoses of these diseases are difficult at times because of the endemic nature of these viruses in most populations. Thus, proving a causal role requires culture from an involved tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23354/abstract/63\">",
"     63",
"    </a>",
"    ], or convincing epidemiologic evidence of a simultaneous epidemic in the geographic area of interest [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23354/abstract/66\">",
"     66",
"    </a>",
"    ]. Laboratory findings are nonspecific and they include leukocytosis, elevated erythrocyte sedimentation rate, and joint fluids with white counts ranging from 2,000 to",
"    <span class=\"nowrap\">",
"     &gt;10,000/mm3.",
"    </span>",
"    Management is symptomatic and supportive for these self-limited disorders.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     ADENOVIRUS INFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adenoviruses comprise a large family of immunotypes because of wide range of clinical illnesses. Only a small number of cases of adenovirus-associated arthritis have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23354/abstract/67\">",
"     67",
"    </a>",
"    ]. Affected patients typically present with mild fever, nonspecific constitutional symptoms, arthralgias, arthritis, and rash. The diagnosis is confirmed by serologic testing. The disease is typically self-limited. Treatment is symptomatic and supportive.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     HERPES VIRUS INFECTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of arthritis syndromes may be associated with the herpesvirus family, including varicella-zoster virus, Epstein-Barr virus, herpes simplex virus, and cytomegalovirus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Varicella",
"    </span>",
"    &nbsp;&mdash;&nbsp;Arthritis associated with chickenpox (varicella) is a rare, but well-described phenomenon that occurs within several days of the onset of the rash [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23354/abstract/68,69\">",
"     68,69",
"    </a>",
"    ]. Monoarticular knee involvement is most common, with swelling, pain, and limitation of motion. The patients with chickenpox and an acute monoarthritis should undergo joint aspiration to be sure there is no underlying bacterial infection. The patients with zoster may have acute and severe joint pain that mimics a septic joint. The pain is thought to be due to viral involvement of the nerve root, rather than the joint itself. Laboratory findings are nondiagnostic [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23354/abstract/68,69\">",
"     68,69",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Epstein-Barr virus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epstein-Barr virus is a gamma herpes virus which is an important cause of infectious mononucleosis and is also implicated in the pathogenesis of certain forms of lymphoma. It has also has been extensively investigated as a possible cause of rheumatoid arthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23354/abstract/70\">",
"     70",
"    </a>",
"    ]. A role in the pathogenesis of lupus has also been of interest, but remains unproven [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23354/abstract/71,72\">",
"     71,72",
"    </a>",
"    ]. Epstein-Barr virus is a double-stranded DNA virus that establishes persistent infection in 90 percent of the human population worldwide [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23354/abstract/73\">",
"     73",
"    </a>",
"    ]. The virus is transmitted in saliva and establishes replicative infection in oropharyngeal cells and latent infection in B-cells.",
"   </p>",
"   <p>",
"    There are different types of latent infections, which show different patterns of expression of the Epstein-Barr viral latent proteins. During early infection, viral capsid antigen IgM antibody is present and as the disease proceeds, IgG viral capsid antigen antibody appears along with Epstein-Barr nuclear antigen antibody and early antigen antibody with the IgM antibody becoming negative if the disease is resolving. Arthralgias are the most common findings with occasional large joint swelling and arthrocentesis may reveal an inflammatory joint fluid [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23354/abstract/60,74\">",
"     60,74",
"    </a>",
"    ]. The joint signs and symptoms are self-limited and treatment is symptomatic for the viral infection itself [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23354/abstract/70,74\">",
"     70,74",
"    </a>",
"    ]. Epstein-Barr viral infections have been implicated in complicating treatment of juvenile idiopathic arthritis, especially for patients on biologic response modifiers [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23354/abstract/21\">",
"     21",
"    </a>",
"    ]. Awareness of a past or present Epstein-Barr infection may help in determining treatment options [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23354/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Herpes simplex virus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Arthritis associated with herpes simplex virus has been reported in a few occasions, all associated with a generalized herpes simplex virus type 1 infection [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23354/abstract/75,76\">",
"     75,76",
"    </a>",
"    ]. In most cases, the disease is self-limited resolving in 10 days to three months.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Cytomegalovirus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cytomegalovirus arthritis is rare, but severe cytomegalovirus polyarthritis has been described in several immunocompromised bone marrow transplant recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23354/abstract/60,75\">",
"     60,75",
"    </a>",
"    ]. These cases were found to have painful warm swollen knees and aspiration yield a noninflammatory synovial fluid. Joint symptoms persisted for several months. CMV reactivation may occur in patients on immunosuppressive agents [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23354/abstract/77\">",
"     77",
"    </a>",
"    ]. Acute arthralgias have also been reported in renal transplantation patients with cytomegaloviral infections [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23354/abstract/60,78,79\">",
"     60,78,79",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/2/29738?source=see_link\">",
"     \"Cytomegalovirus infection in renal transplant recipients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     HIV INFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Human immunodeficiency virus (HIV) is a member of the lentivirus family that also includes caprine arthritis-encephalitis virus, an agent that has been studied as a model of viral-induced arthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23354/abstract/80\">",
"     80",
"    </a>",
"    ]. The World Health Organization estimated that at the end of 2009, 33.3 million people were living with HIV, 2.6 million were newly infected, and 1.8 million died from acquired immune deficiency syndrome (AIDS) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23354/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Rheumatologic complications may be a consequence of improved survival that has followed the introduction of effective anti-retroviral therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23354/abstract/82,83\">",
"     82,83",
"    </a>",
"    ]. Disorders with musculoskeletal manifestations that occur in HIV infected patients include: a painful articular syndrome, reactive arthritis, septic arthritis, the diffuse infiltrative lymphocytosis syndrome (DILS), inflammatory myopathy and drug-induced muscle disease [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23354/abstract/82,84\">",
"     82,84",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A combination of immunodeficiency, immune hyperactivity, and dysregulated production or activity of cytokines such as tumor necrosis factor (TNF) alpha, IL-6, IL-12, interferon (IFN) gamma, and molecular mimicry, may contribute to the rheumatic manifestations of HIV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23354/abstract/82\">",
"     82",
"    </a>",
"    ]. Highly active antiretroviral therapy (HAART) changes the course of HIV infection and may ameliorate some manifestations while contributing to the appearance of others. New syndromes such as the immune reconstitution inflammatory syndrome have emerged. HIV, tuberculosis and syphilis infections offer special epidemiological, clinical, and therapeutic challenges. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/35/23098?source=see_link\">",
"     \"Immune reconstitution inflammatory syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/10/1194?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of tuberculosis in HIV-infected patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/49/3865?source=see_link\">",
"     \"Epidemiology, clinical presentation, and diagnosis of syphilis in the HIV-infected patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Painful articular syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The painful articular syndrome is a self-limited disorder lasting for less than 24 hours in patients with HIV infections [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23354/abstract/84\">",
"     84",
"    </a>",
"    ]. It is reported in up to 10 percent of African HIV seropositive patients. Bone and joint pain is noted, especially in the lower extremities in an asymmetric pattern, which is out of proportion to clinical findings. The etiology is not known and treatment is symptomatic. Rarely, HIV-associated arthralgia progresses to active joint inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23354/abstract/85\">",
"     85",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     HIV-associated arthritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;HIV-associated arthritis was first reported in 1988 and tends to be seen more often in the sub-Saharan African region [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23354/abstract/86\">",
"     86",
"    </a>",
"    ]. It manifests as self-limited arthritis, usually lasting less than six weeks, a duration similar to that observed with other viral arthritides, develops in some patients [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23354/abstract/86,87\">",
"     86,87",
"    </a>",
"    ]. Joints of the lower extremity are usually involved in an oligoarticular pattern. A more prolonged course with joint destruction has been noted in some patients [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23354/abstract/84\">",
"     84",
"    </a>",
"    ]. Should the synovial fluid be aspirated, it is usually found to be sterile. Plain radiographs of the affected joints are normal, without evidence of joint destruction. Those with mild to moderate symptoms may respond to NSAIDs. Low dose glucocorticoids,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"     hydroxychloroquine",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    may be used for those with more severe or prolonged arthritis, but are rarely necessary [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23354/abstract/82\">",
"     82",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Reactive arthritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reactive arthritis (the primary form of spondyloarthritis seen in HIV patients) was first described in 14 patients with AIDS and arthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23354/abstract/88\">",
"     88",
"    </a>",
"    ]. The prevalence in HIV-infected persons ranges from 1.7 to 11.2 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23354/abstract/89\">",
"     89",
"    </a>",
"    ]. Reactive arthritis, in the context of HIV infection, is likely to be due a response to other sexually transmitted or enteric infections, rather than a \"reaction\" to HIV per se. Two population based studies did not suggest a significant increase in the incidence or prevalence of reactive arthritis after adjusting for the risk conferred by sexual activity [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23354/abstract/90\">",
"     90",
"    </a>",
"    ]. HLA-B27 antigen is positive in roughly 70 percent of whites with HIV-associated reactive arthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23354/abstract/91\">",
"     91",
"    </a>",
"    ]. A similar association is not seen in black Africans.",
"   </p>",
"   <p>",
"    The classic triad of arthritis, uveitis, and conjunctivitis is not commonly observed, rather an incomplete form of reactive arthritis occurs [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23354/abstract/92\">",
"     92",
"    </a>",
"    ]. Axial involvement and uveitis is uncommon in HIV-associated spondyloarthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23354/abstract/84\">",
"     84",
"    </a>",
"    ]. Mucocutaneous disease including keratoderma blennorrhagicum and circinate balanitis is often present, especially in HIV patients with a positive HLA-B27 antigen who tend to have worse disease outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23354/abstract/93\">",
"     93",
"    </a>",
"    ]. Otherwise, clinical manifestations of reactive arthritis in HIV-infected patients are similar to those in other populations. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/27/33210?source=see_link\">",
"     \"Reactive arthritis (formerly Reiter syndrome)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Reactive arthritis in HIV is different from HIV-associated arthritis in its chronicity and relapsing nature, by the presence of enthesopathy and mucocutaneous manifestations, and by the HLA-B27 positivity [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23354/abstract/85\">",
"     85",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment of reactive arthritis in the setting of HIV infection is also similar to that in non-HIV infected individuals. Some of the agents that are used to treat reactive arthritis and enthesitis may have some antiviral activity. This has been suggested to be the case for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/50/36649?source=see_link\">",
"     indomethacin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"     hydroxychloroquine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23354/abstract/94-97\">",
"     94-97",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     Methotrexate",
"    </a>",
"    may be used cautiously in HIV patients for both reactive as well as psoriatic arthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23354/abstract/82,98,99\">",
"     82,98,99",
"    </a>",
"    ]. There is a single case report of improvement following use of the anti-tumor necrosis factor monoclonal antibody,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23354/abstract/100\">",
"     100",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/27/33210?source=see_link\">",
"     \"Reactive arthritis (formerly Reiter syndrome)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Septic arthritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nongonococcal bacterial (septic) arthritis in HIV has an incidence of less than one percent [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23354/abstract/101\">",
"     101",
"    </a>",
"    ]. As for non-HIV patients with septic arthritis, the most common organism involved is Staphylococcus aureus, though Streptococcus and Salmonella species, atypical mycobacteria, as well as opportunistic infections may occur, particularly when the CD4 count is less than 200",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23354/abstract/102\">",
"     102",
"    </a>",
"    ]. The usual presentation is monoarticular, though multiple joint involvement has been reported in cases of septic arthritis caused by Salmonella species. The arthritis is usually responsive to conventional antibiotic therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/50/11049?source=see_link\">",
"     \"Septic arthritis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Psoriatic arthritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of psoriatic arthritis (PsA) in HIV-infected patients is 1 to 2 percent, similar to that in non-HIV-infected patients; the severity is often worse in HIV patients, especially those not being treated with antiretroviral therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23354/abstract/103\">",
"     103",
"    </a>",
"    ]. The most commonly and most severely affected joints are generally those of the feet and ankles. As with reactive arthritis, frank synovitis is unusual and enthesitis may be a disabling clinical feature. Axial involvement may occur and be associated with radiographic changes of sacroiliitis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23354/abstract/82\">",
"     82",
"    </a>",
"    ]. Peripheral joint radiographs may reveal \"pencil in cup\" deformities and osteolysis similar to those seen with classic psoriatic arthritis, and these may be present in the absence of frank psoriatic skin involvement (ie, psoriatic arthritis sine psoriasis).",
"   </p>",
"   <p>",
"    In HIV patients, two forms of psoriatic arthritis have been reported. The first is a sustained and aggressive type of arthritis leading to joint erosion, and the second is a more mild and intermittent pattern of joint involvement. There is a strong association of HLA-B27 with pustular psoriasis and psoriatic arthritis in HIV patients [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23354/abstract/103\">",
"     103",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment is the same as in non-HIV infected patients with psoriatic arthritis. Though NSAIDs are generally used as initial treatment for HIV-associated psoriatic arthritis, these agents are often ineffective in controlling the disease and a disease modifying antirheumatic drug (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    [5 to 10 mg once weekly],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    [1 to 2 gm daily]) have been used with success [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23354/abstract/98\">",
"     98",
"    </a>",
"    ]. There is a case report of successful use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil in HIV-associated psoriatic arthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23354/abstract/104\">",
"     104",
"    </a>",
"    ]. Psoralen and pulsed ultraviolet light therapy may be effective for both the skin and joint manifestations.",
"   </p>",
"   <p>",
"    Anti-TNF agents may be beneficial. One study evaluated eight HIV patients with various rheumatic diseases, including three with psoriatic arthritis, who received anti-TNF agents. All patients received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    . All three patients with PsA went on to receive either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"     adalimumab",
"    </a>",
"    and two also received infliximab after failing the other two anti-TNF agents. Both patients had excellent response to infliximab. &nbsp;The side effect profile was overall good, except one patient had transient elevation of the viral RNA [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23354/abstract/105\">",
"     105",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Diffuse infiltrative lymphocytosis syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diffuse infiltrative lymphocytosis syndrome (DILS), a condition which resembles Sj&ouml;gren's syndrome, is seen in 3 to 4 percent of HIV patients. There is massive parotid enlargement secondary to the lymphocytic infiltration [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23354/abstract/106\">",
"     106",
"    </a>",
"    ]. DILS has been seen in all stages of HIV disease irrespective of CD4 counts [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23354/abstract/82,84,106\">",
"     82,84,106",
"    </a>",
"    ]. In addition to the parotid gland swelling, patients often complain of dry mouth, dry eyes, and arthralgia. There may be extraglandular lymphocytic infiltration in the liver, lungs, gastrointestinal tract, kidneys, thymus, and nervous system, leading to hepatitis, renal tubular acidosis, lymphoma, polymyositis, interstitial pneumonitis, and peripheral neuropathy. The incidence of DILS has diminished since the introduction of HAART therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23354/abstract/107\">",
"     107",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    On liver biopsy, extensive CD8 lymphocytic infiltration is seen. HIV patients with DILS differ from patients with idiopathic Sj&ouml;gren's syndrome in that more males than females have been reported with DILS and they tend to be less than 40 year of age. African American patients are more affected. These patients have generalized lymphadenopathy with massive parotid swelling and there is more extraglandular involvement than in idiopathic Sj&ouml;gren's syndrome. Patients with DILS tend to be negative for the rheumatoid factor and anti-SSA or anti-SSB antibodies, and though they may have arthralgias, they usually do not have arthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23354/abstract/108\">",
"     108",
"    </a>",
"    ]. These patients tend to have a slower progression to AIDS, possibly due to suppressed HIV viral replication by the CD8+ lymphocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23354/abstract/109\">",
"     109",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pathogenesis of DILS may be a host immune response associated with HLA-DR5 [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23354/abstract/106\">",
"     106",
"    </a>",
"    ]. Samples from 17 patients (15 males and 2 females) with HIV with moderate to massive bilateral parotid gland swelling showed all patients had polyclonal hypergammaglobulinemia and were found to have CD8 T cell infiltration both in the salivary glands as well as extraglandular tissue. The",
"    <span class=\"nowrap\">",
"     CD4/CD8",
"    </span>",
"    ratio was less than one, and there was an increased ratio of CD4+CD29+ cells to CD4+CD45R+ cells.",
"   </p>",
"   <p>",
"    Therapy for DILS is mostly symptomatic with sialogogues two to three times daily for xerostomia and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/41/24211?source=see_link\">",
"     artificial tears",
"    </a>",
"    for xerophthalmia. These patients are prone to recurrent middle ear, sinus, and oral infections. Thus, careful physical examination and appropriate and timely antibiotics are needed. Corticosteroids are transiently effective for glandular swelling and sicca symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23354/abstract/85\">",
"     85",
"    </a>",
"    ]. Immunosuppressive therapy is reserved for extraglandular involvement, particularly pulmonary or renal disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10996779\">",
"    <span class=\"h2\">",
"     Systemic lupus erythematosus and rheumatoid arthritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Though untreated HIV patients may have multiple antibodies on serologic evaluation including rheumatoid factor (RF), antinuclear antibodies (ANA), cryoglobulins, anti-cardiolipin antibodies, and anti-neutrophil cytoplasmic antibodies, they are rarely of clinical significance. Once patients are started on HAART therapy these low-titer antibodies tend to resolve [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23354/abstract/82,110-112\">",
"     82,110-112",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Though de novo systemic lupus erythematosus and rheumatoid arthritis in HIV-infected patients are rare, if present these diseases remit with low CD4 counts until HAART therapy is introduced [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23354/abstract/113\">",
"     113",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10996842\">",
"    <span class=\"h2\">",
"     Vasculitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polyarteritis nodosa is commonly reported in HIV-infected patients though all vessel involvement has been observed [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23354/abstract/114\">",
"     114",
"    </a>",
"    ]. The clinical presentation is the same in HIV-infected patients as in non-HIV patients.",
"   </p>",
"   <p>",
"    Drug-induced vasculitis has been reported with HAART therapy, specifically with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/38/14952?source=see_link\">",
"     didanosine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23354/abstract/115,116\">",
"     115,116",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Immune reconstitution inflammatory syndromes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since the introduction of effective anti-retroviral therapy, \"immune reconstitution inflammatory syndromes\" (IRIS) have been observed. In the early stages of immune reconstitution there is an increase in CD4+ cells, CD8+ cells, the CD4+ T cell:CD8+ T cell ratio, and cytokines, especially IL-6, TNF&plusmn;, IFN &ge;, and IL-174 leading to IRIS [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23354/abstract/117,118\">",
"     117,118",
"    </a>",
"    ]. IRIS is categorized as either unmasking or paradoxical IRIS.",
"   </p>",
"   <p>",
"    AIDS patients on HAART therapies who develop highly inflammatory reactions to occult infections such as tuberculosis because of reconstitution of their immune system are considered to have unmasking IRIS. If the patient has clinical recrudescence of a successfully treated infection with sterile cultures, there is antigen-driven immune reactivation and the patient is said to have paradoxical IRIS [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23354/abstract/118\">",
"     118",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    New autoimmune or inflammatory disease or flares of preexisting disease such as sarcoidosis or rheumatoid arthritis-like illnesses have been reported in association with reconstitution of T cell mediated immunity [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23354/abstract/119\">",
"     119",
"    </a>",
"    ]. The main risk factors for the development of IRIS are: 1) low baseline CD4+ T cell count (&lt;200",
"    <span class=\"nowrap\">",
"     cells/mL)",
"    </span>",
"    at time of initiation of HAART, 2) significant lowering of viral load (&gt;2 log drop in HIV-1 RNA at 90 days) secondary to HAART, 3) high antigenic load of an opportunistic infection, and 4) initiation of HAART very soon after an opportunistic infection. The average time to IRIS symptoms after initiation of HAART therapy is nine months [",
"    <a class=\"abstract\" href=\"UTD.htm?22/51/23354/abstract/120\">",
"     120",
"    </a>",
"    ]. Most cases of IRIS are self-limited and require minimal therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/35/23098?source=see_link\">",
"     \"Immune reconstitution inflammatory syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H112110450\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Arthralgias and arthritis are common in patients with viral hepatitis. In hepatitis A virus (HAV) infections, arthralgias and rash occur in 10 to 14 percent of patients, but arthritis is extremely rare. Ten to 25 percent of patients with hepatitis B (HBV) develop joint symptoms, often with a rash, and a symmetrical, migratory, or additive arthritis, usually during the prodromal stage of the disease. Joint symptoms tend to persist for days to weeks and resolve with the onset of jaundice. Chronic HBV infection may be associated with more persistent arthritis and other immune complex disorders, such as polyarteritis nodosa, glomerulonephritis, and essential mixed cryoglobulinemia.",
"      <br/>",
"      <br/>",
"      Arthritis is noted in 2 to 20 percent of patients with hepatitis C (HCV). The arthritis is an evanescent rheumatoid-like picture in two-thirds of the cases and an oligoarthritis in the rest. Some patients with chronic HCV infection may develop mixed cryoglobulinemic vasculitis, with associated arthritis. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Hepatitis A virus'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Hepatitis B virus'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Hepatitis C virus'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Human parvovirus B19, the cause of fifth disease or erythema infectiosum, can also cause arthralgias or arthritis. Joint symptoms occur in about 8 percent of infected children and 60 percent of infected adults. Arthralgias or arthritis may accompany or follow the skin eruption. A typical pattern in adults is acute onset symmetrical polyarticular arthritis with the proximal interphalangeal and metacarpophalangeal joints most commonly affected. In children, the arthropathy can be asymmetric and pauciarticular, affecting the knees most often; arthralgias are more frequent than actual joint swelling. The joint symptoms may persist for weeks to occasionally months with resolution, but recurrences are reported. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Parvovirus'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Rubella and rubella vaccine virus are associated with arthritis. The incidence of arthritis with rubella infection is up to 30 percent of females and 6 percent of males. The onset of joint symptoms due to rubella virus is typically abrupt, occurring in most patients within a one-week period before and after the rash. Joint symptoms usually develop approximately two weeks after vaccination with rubella virus vaccine. Joint involvement is similar to that in rheumatic fever being symmetrical, migratory, and additive, with resolution of most joint symptoms within two weeks. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Rubella and rubella vaccine virus'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Alphaviruses that cause",
"      <span class=\"nowrap\">",
"       arthritis/arthralgias",
"      </span>",
"      are globally distributed mosquito-borne RNA viruses causing epidemics of",
"      <span class=\"nowrap\">",
"       polyarthritis/arthralgia,",
"      </span>",
"      with disease emerging or reemerging and increasingly being reported in travelers. A number of agents have been implicated, including Ross River virus, Chikungunya, and others. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Alphaviruses'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The classic findings of dengue virus (DV) infection are an acute febrile illness with headaches and marked muscle and joint pain, sometimes described as \"break-bone fever\". Arthralgias occur in 60 to 80 percent of patients. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/34/18985?source=see_link\">",
"       \"Clinical presentation and diagnosis of dengue virus infections\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Arthritis is an uncommon manifestation of enterovirus infections, such as Coxsackie virus and Echovirus, affecting about 0.1 percent of patients; however, with a large number of patient with this illnesses it can represent a substantial number of cases of nonspecific self-limited arthritis. Joint symptoms commonly accompany some episodes of illnesses associated with fever, myalgias, evanescent rash, and constitutional symptoms, which are presumed due to enterovirus infection. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Enterovirus infections: Coxsackie virus and Echovirus'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Arthralgias are the most common joint manifestation of Epstein-Barr viral infection, with occasional large joint swelling, and arthrocentesis may reveal an inflammatory joint fluid; the joint signs and symptoms are self-limited. Other members of the herpesvirus family with which arthritis has been associated include varicella-zoster virus, herpes simplex virus, and cytomegalovirus. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Epstein-Barr virus'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H13\">",
"       'Varicella'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H15\">",
"       'Herpes simplex virus'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H16\">",
"       'Cytomegalovirus'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Disorders with musculoskeletal manifestations that occur in HIV-infected patients include: a painful articular syndrome, reactive arthritis, septic arthritis, the diffuse infiltrative lymphocytosis syndrome (DILS), inflammatory myopathy and drug-induced muscle disease. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'HIV infection'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H18\">",
"       'Painful articular syndrome'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H19\">",
"       'HIV-associated arthritis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H20\">",
"       'Reactive arthritis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H21\">",
"       'Septic arthritis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H22\">",
"       'Psoriatic arthritis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H23\">",
"       'Diffuse infiltrative lymphocytosis syndrome'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H24\">",
"       'Immune reconstitution inflammatory syndromes'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23354/abstract/1\">",
"      Inman RD, Hodge M, Johnston ME, et al. Arthritis, vasculitis, and cryoglobulinemia associated with relapsing hepatitis A virus infection. Ann Intern Med 1986; 105:700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23354/abstract/2\">",
"      Ganem D, Prince AM. Hepatitis B virus infection--natural history and clinical consequences. N Engl J Med 2004; 350:1118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23354/abstract/3\">",
"      Wright TL, Lau JY. Clinical aspects of hepatitis B virus infection. Lancet 1993; 342:1340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23354/abstract/4\">",
"      Wands JR, Mann E, Alpert E, Isselbacher KJ. The pathogenesis of arthritis associated with acute hepatitis-B surface antigen-positive hepatitis. Complement activation and characterization of circulating immune complexes. J Clin Invest 1975; 55:930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23354/abstract/5\">",
"      Shumaker JB, Goldfinger SE, Alpert E, Isselbacher KJ. Arthritis and rash. Clues to anicteric viral hepatitis. Arch Intern Med 1974; 133:483.",
"     </a>",
"    </li>",
"    <li>",
"     Hsu HH, Feinstone SM, Houfnagle JH. Acute viral hepatitis. In: Mandell, Douglas, and Bennett's Principles and Practices of Infectious Diseases, Fourth Edition, Mandell GL, Bennett JE, Dolin R (Eds), Churchill Livingstone, New York 1995. p.1100.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23354/abstract/7\">",
"      Alarcon GS, Townes AS. Arthritis in viral hepatitis. Report of two cases and review of the literature. Johns Hopkins Med J 1973; 132:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23354/abstract/8\">",
"      Guillevin L, Lhote F, Cohen P, et al. Polyarteritis nodosa related to hepatitis B virus. A prospective study with long-term observation of 41 patients. Medicine (Baltimore) 1995; 74:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23354/abstract/9\">",
"      Johnson RJ, Couser WG. Hepatitis B infection and renal disease: clinical, immunopathogenetic and therapeutic considerations. Kidney Int 1990; 37:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23354/abstract/10\">",
"      Levo Y, Gorevic PD, Kassab HJ, et al. Association between hepatitis B virus and essential mixed cryoglobulinemia. N Engl J Med 1977; 296:1501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23354/abstract/11\">",
"      Cacoub P, Poynard T, Ghillani P, et al. Extrahepatic manifestations of chronic hepatitis C. MULTIVIRC Group. Multidepartment Virus C. Arthritis Rheum 1999; 42:2204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23354/abstract/12\">",
"      Rosner I, Rozenbaum M, Toubi E, et al. The case for hepatitis C arthritis. Semin Arthritis Rheum 2004; 33:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23354/abstract/13\">",
"      Pawlotsky JM, Roudot-Thoraval F, Simmonds P, et al. Extrahepatic immunologic manifestations in chronic hepatitis C and hepatitis C virus serotypes. Ann Intern Med 1995; 122:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23354/abstract/14\">",
"      Rivera J, Garc&iacute;a-Monforte A, Pineda A, Mill&aacute;n N&uacute;&ntilde;ez-Cort&eacute;s J. Arthritis in patients with chronic hepatitis C virus infection. J Rheumatol 1999; 26:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23354/abstract/15\">",
"      Nesher G, Osborn TG, Moore TL. Parvovirus infection mimicking systemic lupus erythematosus. Semin Arthritis Rheum 1995; 24:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23354/abstract/16\">",
"      Moore TL, Bandlamudi R, Alam SM, Nesher G. Parvovirus infection mimicking systemic lupus erythematosus in a pediatric population. Semin Arthritis Rheum 1999; 28:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23354/abstract/17\">",
"      Pavlovic M, Kats A, Cavallo M, Shoenfeld Y. Clinical and molecular evidence for association of SLE with parvovirus B19. Lupus 2010; 19:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23354/abstract/18\">",
"      Naides SJ. Rheumatic manifestations of parvovirus B19 infection. Rheum Dis Clin North Am 1998; 24:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23354/abstract/19\">",
"      T&ouml;r&ouml;k TJ. Parvovirus B19 and human disease. Adv Intern Med 1992; 37:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23354/abstract/20\">",
"      Moore TL. Parvovirus-associated arthritis. Curr Opin Rheumatol 2000; 12:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23354/abstract/21\">",
"      Reed MR, Gilliam BE, Syed RH, Moore TL. Rheumatic manifestations of parvovirus B19 in children. J Ped Infect Dis 2009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23354/abstract/22\">",
"      Young NS, Brown KE. Parvovirus B19. N Engl J Med 2004; 350:586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23354/abstract/23\">",
"      Nikkari S, Luukkainen R, M&ouml;tt&ouml;nen T, et al. Does parvovirus B19 have a role in rheumatoid arthritis? Ann Rheum Dis 1994; 53:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23354/abstract/24\">",
"      Speyer I, Breedveld FC, Dijkmans BA. Human parvovirus B19 infection is not followed by inflammatory joint disease during long term follow-up. A retrospective study of 54 patients. Clin Exp Rheumatol 1998; 16:576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23354/abstract/25\">",
"      S&ouml;derlund M, von Essen R, Haapasaari J, et al. Persistence of parvovirus B19 DNA in synovial membranes of young patients with and without chronic arthropathy. Lancet 1997; 349:1063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23354/abstract/26\">",
"      Takasawa N, Munakata Y, Ishii KK, et al. Human parvovirus B19 transgenic mice become susceptible to polyarthritis. J Immunol 2004; 173:4675.",
"     </a>",
"    </li>",
"    <li>",
"     Gershon AA. Rubella virus. In: Principles and Practices of Infectious Diseases, Third Edition, Mandell GL, Douglas Jr RG, Bennett JE (Eds), Churchill Livingstone, New York 1990. p.1242.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23354/abstract/28\">",
"      Chantler JK, Tingle AJ, Petty RE. Persistent rubella virus infection associated with chronic arthritis in children. N Engl J Med 1985; 313:1117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23354/abstract/29\">",
"      Fraser JR, Cunningham AL, Hayes K, et al. Rubella arthritis in adults. Isolation of virus, cytology and other aspects of the synovial reaction. Clin Exp Rheumatol 1983; 1:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23354/abstract/30\">",
"      Ford DK, da Roza DM, Reid GD, et al. Synovial mononuclear cell responses to rubella antigen in rheumatoid arthritis and unexplained persistent knee arthritis. J Rheumatol 1982; 9:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23354/abstract/31\">",
"      Chantler JK, da Roza DM, Bonnie ME, et al. Sequential studies on synovial lymphocyte stimulation by rubella antigen, and rubella virus isolation in an adult with persistent arthritis. Ann Rheum Dis 1985; 44:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23354/abstract/32\">",
"      Tingle AJ, Chantler JK, Pot KH, et al. Postpartum rubella immunization: association with development of prolonged arthritis, neurological sequelae, and chronic rubella viremia. J Infect Dis 1985; 152:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23354/abstract/33\">",
"      Chantler JK, Ford DK, Tingle AJ. Rubella-associated arthritis: rescue of rubella virus from peripheral blood lymphocytes two years postvaccination. Infect Immun 1981; 32:1274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23354/abstract/34\">",
"      Smith CA, Petty RE, Tingle AJ. Rubella virus and arthritis. Rheum Dis Clin North Am 1987; 13:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23354/abstract/35\">",
"      Ogra PL, Herd JK. Arthritis associated with induced rubella infection. J Immunol 1971; 107:810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23354/abstract/36\">",
"      Mitchell LA, Tingle AJ, Grace M, et al. Rubella virus vaccine associated arthropathy in postpartum immunized women: influence of preimmunization serologic status on development of joint manifestations. J Rheumatol 2000; 27:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23354/abstract/37\">",
"      Ray P, Black S, Shinefield H, et al. Risk of chronic arthropathy among women after rubella vaccination. Vaccine Safety Datalink Team. JAMA 1997; 278:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23354/abstract/38\">",
"      Slater PE. Chronic arthropathy after rubella vaccination in women. False alarm? JAMA 1997; 278:594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23354/abstract/39\">",
"      Spruance SL, Metcalf R, Smith CB, et al. Chronic arthropathy associated with rubella vaccination. Arthritis Rheum 1977; 20:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23354/abstract/40\">",
"      Grahame R, Armstrong R, Simmons N, et al. Chronic arthritis associated with the presence of intrasynovial rubella virus. Ann Rheum Dis 1983; 42:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23354/abstract/41\">",
"      Suhrbier A, La Linn M. Clinical and pathologic aspects of arthritis due to Ross River virus and other alphaviruses. Curr Opin Rheumatol 2004; 16:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23354/abstract/42\">",
"      Toivanen A. Alphaviruses: an emerging cause of arthritis? Curr Opin Rheumatol 2008; 20:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23354/abstract/43\">",
"      Hoarau JJ, Jaffar Bandjee MC, Krejbich Trotot P, et al. Persistent chronic inflammation and infection by Chikungunya arthritogenic alphavirus in spite of a robust host immune response. J Immunol 2010; 184:5914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23354/abstract/44\">",
"      Soden M, Vasudevan H, Roberts B, et al. Detection of viral ribonucleic acid and histologic analysis of inflamed synovium in Ross River virus infection. Arthritis Rheum 2000; 43:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23354/abstract/45\">",
"      Way SJ, Lidbury BA, Banyer JL. Persistent Ross River virus infection of murine macrophages: an in vitro model for the study of viral relapse and immune modulation during long-term infection. Virology 2002; 301:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23354/abstract/46\">",
"      Gerszten RE, Garcia-Zepeda EA, Lim YC, et al. MCP-1 and IL-8 trigger firm adhesion of monocytes to vascular endothelium under flow conditions. Nature 1999; 398:718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23354/abstract/47\">",
"      Mateo L, La Linn M, McColl SR, et al. An arthrogenic alphavirus induces monocyte chemoattractant protein-1 and interleukin-8. Intervirology 2000; 43:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23354/abstract/48\">",
"      Linn ML, Mateo L, Gardner J, Suhrbier A. Alphavirus-specific cytotoxic T lymphocytes recognize a cross-reactive epitope from the capsid protein and can eliminate virus from persistently infected macrophages. J Virol 1998; 72:5146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23354/abstract/49\">",
"      ROBINSON MC. An epidemic of virus disease in Southern Province, Tanganyika Territory, in 1952-53. I. Clinical features. Trans R Soc Trop Med Hyg 1955; 49:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23354/abstract/50\">",
"      Bodenmann P, Genton B. Chikungunya: an epidemic in real time. Lancet 2006; 368:258.",
"     </a>",
"    </li>",
"    <li>",
"     Johnston REPC. Alphaviruses. In: Virology, Third Edition, Fields BN, Knipe DM, Howley PM, et al (Eds), Lippincott-Raven, Philadelphia 1996. p.843.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23354/abstract/52\">",
"      Mylonas AD, Brown AM, Carthew TL, et al. Natural history of Ross River virus-induced epidemic polyarthritis. Med J Aust 2002; 177:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23354/abstract/53\">",
"      Brighton SW, Prozesky OW, de la Harpe AL. Chikungunya virus infection. A retrospective study of 107 cases. S Afr Med J 1983; 63:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23354/abstract/54\">",
"      Simon F, Parola P, Grandadam M, et al. Chikungunya infection: an emerging rheumatism among travelers returned from Indian Ocean islands. Report of 47 cases. Medicine (Baltimore) 2007; 86:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23354/abstract/55\">",
"      Chopra A, Anuradha V, Lagoo-Joshi V, et al. Chikungunya virus aches and pains: an emerging challenge. Arthritis Rheum 2008; 58:2921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23354/abstract/56\">",
"      Harley D, Sleigh A, Ritchie S. Ross River virus transmission, infection, and disease: a cross-disciplinary review. Clin Microbiol Rev 2001; 14:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23354/abstract/57\">",
"      Rigau-P&eacute;rez JG. The early use of break-bone fever (Quebranta huesos, 1771) and dengue (1801) in Spanish. Am J Trop Med Hyg 1998; 59:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23354/abstract/58\">",
"      Kalayanarooj S, Vaughn DW, Nimmannitya S, et al. Early clinical and laboratory indicators of acute dengue illness. J Infect Dis 1997; 176:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23354/abstract/59\">",
"      Schmidt AC. Response to dengue fever--the good, the bad, and the ugly? N Engl J Med 2010; 363:484.",
"     </a>",
"    </li>",
"    <li>",
"     Naides SJ. Viral arthritis. In: Kelley's Textbook of Rheumatology, Seventh Edition, Harris ED, Budd RC, Genovese MC, et al (Eds), Elseveier-Saunder, Philadelphia 2005. p.1688.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23354/abstract/61\">",
"      Gordon SC, Lauter CB. Mumps arthritis: a review of the literature. Rev Infect Dis 1984; 6:338.",
"     </a>",
"    </li>",
"    <li>",
"     Zeichhardt H, Grunert HP. Enteroviruses. In: Infectious Disease Textbook, First Edition, Armstrong D, Cohen J (Eds), Mosby, London 1999. p.8212.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23354/abstract/63\">",
"      Kujala G, Newman JH. Isolation of echovirus type 11 from synovial fluid in acute monocytic arthritis. Arthritis Rheum 1985; 28:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23354/abstract/64\">",
"      Blotzer JW, Myers AR. Echovirus-associated polyarthritis. Report of a case with synovial fluid and synovial histologic characterization. Arthritis Rheum 1978; 21:978.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23354/abstract/65\">",
"      Hurst NP, Martynoga AG, Nuki G, et al. Coxsackie B infection and arthritis. Br Med J (Clin Res Ed) 1983; 286:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23354/abstract/66\">",
"      Ackerson BK, Raghunathan R, Keller MA, et al. Echovirus 11 arthritis in a patient with X-linked agammaglobulinemia. Pediatr Infect Dis J 1987; 6:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23354/abstract/67\">",
"      Fraser KJ, Clarris BJ, Muirden KD, et al. A persistent adenovirus type 1 infection in synovial tissue from an immunodeficient patient with chronic, rheumatoid-like polyarthritis. Arthritis Rheum 1985; 28:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23354/abstract/68\">",
"      Fierman AH. Varicella-associated arthritis occurring before the exanthem. Case report and literature review. Clin Pediatr (Phila) 1990; 29:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23354/abstract/69\">",
"      Pascual-G&oacute;mez E. Identification of large mononuclear cells in varicella arthritis. Arthritis Rheum 1980; 23:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23354/abstract/70\">",
"      Callan MF. Epstein-Barr virus, arthritis, and the development of lymphoma in arthritis patients. Curr Opin Rheumatol 2004; 16:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23354/abstract/71\">",
"      Harley JB, James JA. Everyone comes from somewhere: systemic lupus erythematosus and Epstein-Barr virus induction of host interferon and humoral anti-Epstein-Barr nuclear antigen 1 immunity. Arthritis Rheum 2010; 62:1571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23354/abstract/72\">",
"      Quan TE, Roman RM, Rudenga BJ, et al. Epstein-Barr virus promotes interferon-alpha production by plasmacytoid dendritic cells. Arthritis Rheum 2010; 62:1693.",
"     </a>",
"    </li>",
"    <li>",
"     Rickinson AB, Kieff E. Epstein-Barr virus. In: Virology, Third Edition, Fields BN, Knipe DM, Howley PM, et al (Eds), Lippincott-Raven, Philadelphia 1996. p.2397.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23354/abstract/74\">",
"      Sigal LH, Steere AC, Niederman JC. Symmetric polyarthritis associated with heterophile-negative infectious mononucleosis. Arthritis Rheum 1983; 26:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23354/abstract/75\">",
"      Friedman HM, Pincus T, Gibilisco P, et al. Acute monoarticular arthritis caused by herpes simplex virus and cytomegalovirus. Am J Med 1980; 69:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23354/abstract/76\">",
"      Remafedi G, Muldoon RL. Acute monarticular arthritis caused by herpes simplex virus type I. Pediatrics 1983; 72:882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23354/abstract/77\">",
"      Eisenstein EM, Wolf DG. Cytomegalovirus infection in pediatric rheumatic diseases: a review. Pediatr Rheumatol Online J 2010; 8:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23354/abstract/78\">",
"      Fiala M, Payne JE, Berne TV, et al. Epidemiology of cytomegalovirus infection after transplantation and immunosuppression. J Infect Dis 1975; 132:421.",
"     </a>",
"    </li>",
"    <li>",
"     Rubin RH. Clinical approach to infection in the compromised host. In: Infection in the organ transplant recipient, First Edition, Rubin RH, Young NS (Eds), Kluwer Academic Press, New York 2002. p.573.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23354/abstract/80\">",
"      Michaels FH, Banks KL, Reitz MS Jr. Lessons from caprine and ovine retrovirus infections. Rheum Dis Clin North Am 1991; 17:5.",
"     </a>",
"    </li>",
"    <li>",
"     UNAIDS/WHO. Global Report: 2009.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23354/abstract/82\">",
"      Nguyen BY, Reveille JD. Rheumatic manifestations associated with HIV in the highly active antiretroviral therapy era. Curr Opin Rheumatol 2009; 21:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23354/abstract/83\">",
"      Centers for Disease Control and Prevention (CDC). The Global HIV/AIDS pandemic, 2006. MMWR Morb Mortal Wkly Rep 2006; 55:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23354/abstract/84\">",
"      Reveille JD. The changing spectrum of rheumatic disease in human immunodeficiency virus infection. Semin Arthritis Rheum 2000; 30:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23354/abstract/85\">",
"      Maganti RM, Reveille JD, Williams FM. Therapy insight: the changing spectrum of rheumatic disease in HIV infection. Nat Clin Pract Rheumatol 2008; 4:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23354/abstract/86\">",
"      Rynes RI, Goldenberg DL, DiGiacomo R, et al. Acquired immunodeficiency syndrome-associated arthritis. Am J Med 1988; 84:810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23354/abstract/87\">",
"      Berman A, Cahn P, Perez H, et al. Human immunodeficiency virus infection associated arthritis: clinical characteristics. J Rheumatol 1999; 26:1158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23354/abstract/88\">",
"      Winchester R, Bernstein DH, Fischer HD, et al. The co-occurrence of Reiter's syndrome and acquired immunodeficiency. Ann Intern Med 1987; 106:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23354/abstract/89\">",
"      Cuellar ML, Espinoza LR. Rheumatic manifestations of HIV-AIDS. Baillieres Best Pract Res Clin Rheumatol 2000; 14:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23354/abstract/90\">",
"      Clark MR, Solinger AM, Hochberg MC. Human immunodeficiency virus infection is not associated with Reiter's syndrome. Data from three large cohort studies. Rheum Dis Clin North Am 1992; 18:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23354/abstract/91\">",
"      Brancato L, Itescu S, Skovron ML, et al. Aspects of the spectrum, prevalence and disease susceptibility determinants of Reiter's syndrome and related disorders associated with HIV infection. Rheumatol Int 1989; 9:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23354/abstract/92\">",
"      Solomon G, Brancato L, Winchester R. An approach to the human immunodeficiency virus-positive patient with a spondyloarthropathic disease. Rheum Dis Clin North Am 1991; 17:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23354/abstract/93\">",
"      Njobvu P, McGill P. Human immunodeficiency virus related reactive arthritis in Zambia. J Rheumatol 2005; 32:1299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23354/abstract/94\">",
"      Bourinbaiar AS, Lee-Huang S. The non-steroidal anti-inflammatory drug, indomethacin, as an inhibitor of HIV replication. FEBS Lett 1995; 360:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23354/abstract/95\">",
"      Youssef PP, Bertouch JV, Jones PD. Successful treatment of human immunodeficiency virus-associated Reiter's syndrome with sulfasalazine. Arthritis Rheum 1992; 35:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23354/abstract/96\">",
"      Disla E, Rhim HR, Reddy A, Taranta A. Improvement in CD4 lymphocyte count in HIV-Reiter's syndrome after treatment with sulfasalazine. J Rheumatol 1994; 21:662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23354/abstract/97\">",
"      Sperber K, Kalb TH, Stecher VJ, et al. Inhibition of human immunodeficiency virus type 1 replication by hydroxychloroquine in T cells and monocytes. AIDS Res Hum Retroviruses 1993; 9:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23354/abstract/98\">",
"      Maurer TA, Zackheim HS, Tuffanelli L, Berger TG. The use of methotrexate for treatment of psoriasis in patients with HIV infection. J Am Acad Dermatol 1994; 31:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23354/abstract/99\">",
"      Masson C, Chennebault JM, Leclech C. Is HIV infection contraindication to the use of methotrexate in psoriatic arthritis? J Rheumatol 1995; 22:2191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23354/abstract/100\">",
"      Gaylis N. Infliximab in the treatment of an HIV positive patient with Reiter's syndrome. J Rheumatol 2003; 30:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23354/abstract/101\">",
"      Neumann S, Kreth F, Schubert S, et al. Reiter's syndrome as a manifestation of an immune reconstitution syndrome in an HIV-infected patient: successful treatment with doxycycline. Clin Infect Dis 2003; 36:1628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23354/abstract/102\">",
"      Zalavras CG, Dellamaggiora R, Patzakis MJ, et al. Septic arthritis in patients with human immunodeficiency virus. Clin Orthop Relat Res 2006; 451:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23354/abstract/103\">",
"      Reveille JD, Conant MA, Duvic M. Human immunodeficiency virus-associated psoriasis, psoriatic arthritis, and Reiter's syndrome: a disease continuum? Arthritis Rheum 1990; 33:1574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23354/abstract/104\">",
"      Forman SB, Higginson R, Garrett AB. Psoriasis and psoriatic arthritis in a patient with HIV: response to mycophenolate mofetil treatment. J Drugs Dermatol 2008; 7:972.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23354/abstract/105\">",
"      Cepeda EJ, Williams FM, Ishimori ML, et al. The use of anti-tumour necrosis factor therapy in HIV-positive individuals with rheumatic disease. Ann Rheum Dis 2008; 67:710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23354/abstract/106\">",
"      Itescu S, Brancato LJ, Buxbaum J, et al. A diffuse infiltrative CD8 lymphocytosis syndrome in human immunodeficiency virus (HIV) infection: a host immune response associated with HLA-DR5. Ann Intern Med 1990; 112:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23354/abstract/107\">",
"      Basu D, Williams FM, Ahn CW, Reveille JD. Changing spectrum of the diffuse infiltrative lymphocytosis syndrome. Arthritis Rheum 2006; 55:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23354/abstract/108\">",
"      Atkinson JC, Schi&oslash;dt M, Robataille S, et al. Salivary autoantibodies in HIV-associated salivary gland disease. J Oral Pathol Med 1993; 22:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23354/abstract/109\">",
"      Itescu S, Dalton J, Zhang HZ, Winchester R. Tissue infiltration in a CD8 lymphocytosis syndrome associated with human immunodeficiency virus-1 infection has the phenotypic appearance of an antigenically driven response. J Clin Invest 1993; 91:2216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23354/abstract/110\">",
"      Kaye BR. Rheumatologic manifestations of infection with human immunodeficiency virus (HIV). Ann Intern Med 1989; 111:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23354/abstract/111\">",
"      Fabris P, Tositti G, Giordani MT, et al. Prevalence and clinical significance of circulating cryoglobulins in HIV-positive patients with and without co-infection with hepatitis C virus. J Med Virol 2003; 69:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23354/abstract/112\">",
"      Klaassen RJ, Goldschmeding R, Dolman KM, et al. Anti-neutrophil cytoplasmic autoantibodies in patients with symptomatic HIV infection. Clin Exp Immunol 1992; 87:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23354/abstract/113\">",
"      Hazarika I, Chakravarty BP, Dutta S, Mahanta N. Emergence of manifestations of HIV infection in a case of systemic lupus erythematosus following treatment with IV cyclophosphamide. Clin Rheumatol 2006; 25:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23354/abstract/114\">",
"      Chetty R, Batitang S, Nair R. Large artery vasculopathy in HIV-positive patients: another vasculitic enigma. Hum Pathol 2000; 31:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23354/abstract/115\">",
"      Herranz P, Fern&aacute;ndez-D&iacute;az ML, de Lucas R, et al. Cutaneous vasculitis associated with didanosine. Lancet 1994; 344:680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23354/abstract/116\">",
"      Torres RA, Lin RY, Lee M, Barr MR. Zidovudine-induced leukocytoclastic vasculitis. Arch Intern Med 1992; 152:850.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23354/abstract/117\">",
"      French MA, Lewin SR, Dykstra C, et al. Graves' disease during immune reconstitution after highly active antiretroviral therapy for HIV infection: evidence of thymic dysfunction. AIDS Res Hum Retroviruses 2004; 20:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23354/abstract/118\">",
"      Bonham S, Meya DB, Bohjanen PR, Boulware DR. Biomarkers of HIV Immune Reconstitution Inflammatory Syndrome. Biomark Med 2008; 2:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23354/abstract/119\">",
"      Calabrese LH, Naides SJ. Viral arthritis. Infect Dis Clin North Am 2005; 19:963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/51/23354/abstract/120\">",
"      Calabrese LH, Kirchner E, Shrestha R. Rheumatic complications of human immunodeficiency virus infection in the era of highly active antiretroviral therapy: emergence of a new syndrome of immune reconstitution and changing patterns of disease. Semin Arthritis Rheum 2005; 35:166.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5584 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.234.146.186-B869A8C837-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_51_23354=[""].join("\n");
var outline_f22_51_23354=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H112110450\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      HEPATITIS A VIRUS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      HEPATITIS B VIRUS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      HEPATITIS C VIRUS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PARVOVIRUS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      RUBELLA AND RUBELLA VACCINE VIRUS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      ALPHAVIRUSES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      DENGUE VIRUS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      MUMPS VIRUS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      ENTEROVIRUS INFECTIONS: COXSACKIE VIRUS AND ECHOVIRUS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      ADENOVIRUS INFECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      HERPES VIRUS INFECTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Varicella",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Epstein-Barr virus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Herpes simplex virus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Cytomegalovirus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      HIV INFECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Painful articular syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      HIV-associated arthritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Reactive arthritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Septic arthritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Psoriatic arthritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Diffuse infiltrative lymphocytosis syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10996779\">",
"      Systemic lupus erythematosus and rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10996842\">",
"      Vasculitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Immune reconstitution inflammatory syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H112110450\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/13/15576?source=related_link\">",
"      Chikungunya fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/15/34040?source=related_link\">",
"      Clinical manifestations and diagnosis of the mixed cryoglobulinemia syndrome (essential mixed cryoglobulinemia)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/54/22377?source=related_link\">",
"      Clinical manifestations and pathogenesis of human parvovirus B19 infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/34/18985?source=related_link\">",
"      Clinical presentation and diagnosis of dengue virus infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/2/29738?source=related_link\">",
"      Cytomegalovirus infection in renal transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/10/1194?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of tuberculosis in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/61/8154?source=related_link\">",
"      Epidemiology, clinical manifestations, diagnosis and management of mumps",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/49/3865?source=related_link\">",
"      Epidemiology, clinical presentation, and diagnosis of syphilis in the HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/35/23098?source=related_link\">",
"      Immune reconstitution inflammatory syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/33/1558?source=related_link\">",
"      Pathogenesis and diagnosis of viral arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/27/33210?source=related_link\">",
"      Reactive arthritis (formerly Reiter syndrome)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/8/41095?source=related_link\">",
"      Ross River virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/14/26855?source=related_link\">",
"      Rubella",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/50/11049?source=related_link\">",
"      Septic arthritis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/52/36682?source=related_link\">",
"      Treatment of the mixed cryoglobulinemia syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_51_23355="Lumbosacral radiculopathies";
var content_f22_51_23355=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F75974&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F75974&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Symptoms and signs of lumbosacral radiculopathies",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Nerve",
"       </td>",
"       <td class=\"subtitle1\">",
"        Symptoms",
"       </td>",
"       <td class=\"subtitle1\">",
"        Signs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        L5",
"       </td>",
"       <td>",
"        Back pain radiating down the lateral leg to foot",
"       </td>",
"       <td>",
"        Decreased foot dorsiflexion, toe extension, foot inversion and eversion; mild weakness of leg abduction in severe cases",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        S1",
"       </td>",
"       <td>",
"        Pain radiating down the posterior leg to foot; leg pain greater than back pain",
"       </td>",
"       <td>",
"        Decreased leg extension, foot inversion, plantar flexion, and toe flexion; decreased sensation in the posterior leg and lateral foot; loss of ankle jerk",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        L2-4",
"       </td>",
"       <td>",
"        Acute back pain radiating around the anterior leg into the knee and possibly foot",
"       </td>",
"       <td>",
"        Decreased hip flexion, knee extension, leg abduction; decreased sensation in the anterior thigh down the medial aspect of the shin; diminished knee jerk in severe cases",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        S2-4",
"       </td>",
"       <td>",
"        Sacral or buttock pain radiating down the posterior leg or into the perineum",
"       </td>",
"       <td>",
"        Minimal weakness; bowel and bladder dysfunction",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_51_23355=[""].join("\n");
var outline_f22_51_23355=null;
var title_f22_51_23356="MRCP and EUS for choledoch";
var content_f22_51_23356=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F73388&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F73388&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Advantages and disadvantages associated with MRCP and EUS for the evaluation of choledocholithiasis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        MRCP",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Advantages",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Noninvasive",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Intravenous contrast usually given but not required",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Established technique, widely available",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Disadvantages",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Time consuming",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Contraindications such as cardiac pacemaker/defibrillator, intracranial metal clips",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        False-positive studies (eg, intraductal artifacts such as air or blood, image reconstruction artifacts, motion artifacts)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        False-negative studies (eg, stones in dilated CBD or stones &lt;5 mm in the distal duct may not be visualized well)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        EUS",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Advantages",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Very high resolution (0.1 mm) compared with MRCP (1.5 mm)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Dynamic imaging allowing manipulation and magnification of image for better visualization",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        ERCP can potentially be performed in the same setting for stone removal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Can be performed at the bedside in critically ill patients",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Disadvantages",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        More invasive than MRCP",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Need for sedation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Risks associated with sedation (eg, cardiopulmonary compromise) and endoscopy (eg, bleeding and perforation)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Limited availability of equipment and trained endosonographers",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Not possible or limited role in altered anatomy (eg, pyloric stenosis, Roux-en-Y bypass)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CBD: common bile duct; ERCP: endoscopic retrograde cholangiopancreatography; EUS: endoscopic ultrasound; MRCP: magnetic endoscopic retrograde cholangiopancreatography.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of ML Freeman, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_51_23356=[""].join("\n");
var outline_f22_51_23356=null;
var title_f22_51_23357="Anthrax PEP";
var content_f22_51_23357=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F58905&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F58905&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Recommended initial antimicrobial agent and anthrax vaccine absorbed (AVA) dosages for postexposure prophylaxis (PEP) after exposure to aerosolized",
"    <em>",
"     Bacillus anthracis",
"    </em>",
"    spores",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Population",
"       </td>",
"       <td class=\"subtitle1\">",
"        Antimicrobials for 60-day* PEP",
"       </td>",
"       <td class=\"subtitle1\">",
"        AVA dosage and route&bull;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        Adults (18-65 yrs)",
"       </td>",
"       <td>",
"        <strong>",
"         One of the following for 60 days:",
"        </strong>",
"       </td>",
"       <td rowspan=\"3\">",
"        3-dose subcutaneous (SC) series: first dose administered as soon as possible, second and third doses administered 2 and 4 wks after the first dose",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ciprofloxacin,&Delta; 500 mg orally twice daily",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Doxycycline, 100 mg orally twice daily",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"4\">",
"        Pregnant women&loz;",
"       </td>",
"       <td>",
"        <strong>",
"         One of the following for 60 days:",
"        </strong>",
"       </td>",
"       <td rowspan=\"4\">",
"        3-dose SC series; first dose administered as soon as possible, second and third doses administered 2 and 4 wks after the first dose",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ciprofloxacin, 500 mg orally twice daily",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Doxycycline, 100 mg orally twice daily",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Amoxicillin,&sect; 500 mg every 8 hrs",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"7\">",
"        Children (&lt;18 yrs)&yen;",
"       </td>",
"       <td>",
"        <strong>",
"         One of the following for 60 days:",
"        </strong>",
"       </td>",
"       <td rowspan=\"7\">",
"        Recommendations for use of AVA in children are made on an event-by-event basis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ciprofloxacin,&Delta;&yen; 15 mg/kg every 12 hrs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Doxycycline,&yen; (maximum of 100 mg/dose)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        &gt;8 yrs and &gt;45 kg: 100 mg every 12 hrs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        &gt;8 yrs and &le;45 kg: 2.2 mg/kg every 12 hrs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        &le;8 yrs: 2.2 mg/kg every 12 hrs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Amoxicillin,&sect; ** 45 mg/kg/day orally divided into 3 daily doses given every 8 hrs; each dose should not exceed 500 mg",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Antimicrobials should continue for 14 days after administration of the third dose of vaccine.",
"     <br>",
"      <span class=\"bullet\">",
"       &bull;",
"      </span>",
"      AVA used for PEP must be administered subcutaneously.",
"      <br>",
"       &Delta; Levofloxacin is a second-line antimicrobial agent for PEP for persons aged &ge;6 mos with medical issues (eg, tolerance or resistance to ciprofloxacin) that indicate its use.",
"       <em>",
"        Children:",
"       </em>",
"       16 mg/kg/day divided every 12 hrs; each dose should not exceed 250 mg.",
"       <em>",
"        Adults:",
"       </em>",
"       500 mg every 24 hrs. Safety data on extended use of levofloxacin in any population for &gt;28 days are limited; therefore, levofloxacin PEP should only be used when the benefit outweighs the risk.",
"       <br>",
"        <span class=\"lozenge\">",
"         &loz;",
"        </span>",
"        The antimicrobial of choice for initial prophylactic therapy among pregnant women is ciprofloxacin. Doxycycline should be used with caution in asymptomatic pregnant women and only when other appropriate antimicrobial drugs are contraindicated. Although tetracyclines are not recommended during pregnancy, their use might be indicated for life-threatening illness.",
"        <br>",
"         &sect; If susceptibility testing demonstrates an amoxicillin MIC &le;0.125 &mu;g/mL, oral amoxicillin should be used to complete therapy.",
"         <br>",
"          &yen; Use of tetracyclines and fluoroquinolones in children can have adverse effects. These effects must be weighed carefully against the risk for developing life-threatening disease. If exposure to",
"          <em>",
"           B. anthracis",
"          </em>",
"          is confirmed, children may be treated initially with ciprofloxacin or doxycycline as prophylaxis. However, amoxicillin is preferred for antimicrobial PEP in children when susceptibility testing indicates that the",
"          <em>",
"           B. anthracis",
"          </em>",
"          isolate is susceptible to penicillins.",
"          <br>",
"            Each ciprofloxacin dose should not exceed 500 mg, or 1 g/day.",
"           <br>",
"             In 1991, the American Academy of Pediatrics (AAP) amended the recommendation to allow treatment of young children with tetracyclines for serious infections such as Rocky Mountain spotted fever for which doxycycline might be indicated. Doxycycline is preferred for its twice daily dosage and low incidence of gastrointestinal side effects.",
"            <br>",
"             ** Because of the lack of data on amoxicillin dosages for treating anthrax (and the associated high mortality rate), AAP recommends a higher dosage of 80 mg/kg/day, divided into 3 daily doses; each dose should not exceed 500 mg. If this higher dosage of amoxicillin is used, recipients should be carefully monitored for side effects from long-term treatment.",
"            </br>",
"           </br>",
"          </br>",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Use of Anthrax Vaccine in the United States: Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. MMWR Recomm Rep 2010; 59(RR-6):1-36.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_51_23357=[""].join("\n");
var outline_f22_51_23357=null;
var title_f22_51_23358="Diagnostic algorithm for HCC";
var content_f22_51_23358=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F76105&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F76105&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 549px\">",
"   <div class=\"ttl\">",
"    Algorithm for investigation of small nodules found on screening in patients at risk for hepatocellular carcinoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 529px; height: 421px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CT: computed tomography; HCC: hepatocellular carcinoma; MDCT: multidetector CT scan; MRI: magnetic resonance imaging; US: ultrasound.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Bruix J, Sherman M. Management of Hepatocellular Carcinoma: An Update. Hepatology 2010. Copyright &copy; 2010 John Wiley &amp; Sons.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_51_23358=[""].join("\n");
var outline_f22_51_23358=null;
var title_f22_51_23359="Treatment of PBC";
var content_f22_51_23359=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F65423&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F65423&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Algorithm for the treatment of primary biliary cirrhosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 388px; height: 577px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_51_23359=[""].join("\n");
var outline_f22_51_23359=null;
